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Abstract  
 
A robust method for global metabolomics in urine using liquid chromatography (LC) with 
electrospray ionization (ESI) in positive ionization, tandem mass spectrometry (MS/MS) and 
quadrupole time-of-flight (Q-TOF) was developed. In addition, this method was applicable 
for negative ionization detection as performed by Siv M. Løvoll [1]. 
 
By using an ACE C18 pentaflourphenyl (PFP) (250 x 2.1 mm, 3 um) column and separation 
over an hour long gradient, approximately 6000 molecular features were detected in 
positive mode, in a single batch of urine. Urine sample preparation was performed by using 
0.22 μm cellulose acetate spin filters before injecting 8.0 μL onto the column. The method 
showed promising performance characteristics making it a strong candidate for future 
urinary metabolome analysis.   
 
The usefulness of the method was demonstrated by showing significant clustering of human 
urinary metabolites in 15 subjects after eating a standardized diet for 24 hours. These novel 
results indicate a surprisingly fast diet-dependent change in the metabolome.  
 
Using the method developed, in combination with a broad range of analytical techniques, an 
unknown compound in a black urine sample from a patient was also successfully identified 
as the metabolite, 5-aminosalicyclic acid (5-ASA). Even though this compound turned out to 
originate from an anti-inflammatory drug, the workflow shows strong potential as a method 
to identify new diagnostic biomarkers in the future. 
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Abbreviations 
 
 
5-ASA 5-aminosalicylic acid 
AA Acetic acid 
ACU Alcaptonuria 
APCI Atmospheric pressure chemical ionization 
CV Coefficient of variance 
EI Electron ionization 
EIC Extracted ion chromatogram 
ESI Electrospray ionization 
FA Formic acid 
FT-IR Fourier Transform Infrared Spectroscopy 
GC Gas chromatography 
HILIC Hydrophilic interaction liquid chromatography 
LC Liquid chromatography 
ID Inner diameter 
IEM Inborn errors of metabolism 
m/z Mass to charge ratio 
MeOH Methanol 
MFE Molecular feature extraction 
MP Mobile phase 
MPP Mass profiler professional 
MS Mass spectrometry 
MS 1 Single mass spectrometry 
MS/MS Tandem mass spectrometry 
MW Molecular mass 
N-Ac-5-ASA N-Acetylated-5-aminosalicyclic acid 
NBS Newborn screening 
NMR Nuclear magnetic resonance 
PFP Pentafluorophenyl 
PKU Phenylketonuria 
PVDF Polyvinylidene fluoride 
Q-TOF Quadrupol- time of flight 
RP Reversed phase 
SP Stationary phase 
TIC Total ion chromatogram 
tR Retention time 
UV Ultra violet 
XRD X-Ray Diffraction 
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1 Introduction 
 
Inborn errors of metabolism (IEM) constitute a large group of genetic diseases that involve 
change in the complex biochemical and metabolic pathways of living cells [2]. The individual 
IEM are relatively rare, but are collectively common. If not diagnosed early, morbidity and 
mortality of newborns may result from the disorder. Symptoms are often diffuse and 
diagnostic methods are difficult. Newborn screening (NBS) is performed for specific IEM to 
allow early diagnosis and treatment. Starting more than 40 years ago, every Norwegian 
newborn has been screened for 2 diseases, phenylketonuria (PKU) and hypothyroidism. 
Since 2012 the screening has been expanded to include 23 different diseases of which 20 are 
IEM [3]. All of these disorders can be treated, some with great success.  
 
 Metabolomics involves the systematic study of all metabolites in a given organism or 
biological sample [4]. Metabolomics is an emerging field and an important tool for clinical 
research into human diseases. This development is allowed by sensitive and accurate 
analytical methods like mass spectrometry (MS) in tandem with chemometric software. This 
combination allows the identification and comparison of thousands of metabolites 
simultaneously. Metabolomics has therefore become a method to discover biomarkers that 
can be used to diagnose diseases, including IEM. Table 1 lists some definitions commonly 
used in this thesis. 
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Table 1: Important definitions in the field of metabolomics used in this thesis 
Metabolism Involves the multitude of complex biochemical processes that occur in living 
cells in order to maintain essential cellular activities [2]. 
Metabolites Small molecules that are products and intermediates of metabolic reactions 
present in living organisms [5]. 
Metabolome Involves the complete set of endogenous low-molecular weight 
components in a biological sample such as cells, tissue, urine or plasma [6]. 
Metabolomics Complete analysis of the whole metabolome under a given set of conditions 
[7]. 
Biomarker A characteristic that can be measured in a biological sample as an indicator 
of normal or pathogenic processes, as well a response to therapeutic 
interventions [8]. 
Differential 
diagnosis 
Different diseases that can all cause the clinical symptoms presented.  
 
However, the use of metabolomics for disease diagnostics is not a recent invention. Already 
in 4000 BC urine was already an important marker for health and disease [9]. Obviously, 
there were no advanced analytical instrumentation like LC or MS to measure diagnostic 
metabolites, but color, smell and taste were used to examine urine. Specific characteristics 
of urine corresponded to certain diseases and physicians began to diagnose urine samples 
without prior consultation with the patient. In 1934 the Norwegian biochemist Ivar A. Følling 
discovered excess amounts of phenylalanine in patients with PKU. Little did he know that he 
had just performed the first screening for IEM and that phenylalanine would still be a 
biomarker for PKU almost 80 years later!  
 
The motivation for this thesis was that the Section for Inborn Errors of Metabolism wanted 
to develop a method suitable for studying the urinary metabolome using a combination of LC 
and Q-TOF. For IEM, the identification of new diseases relies to a large extent on the 
identification of accumulated metabolites in body fluids of affected patients. In order to 
detect new biomarkers for diseases, the metabolome of the healthy state may be compared 
to the metabolome of a disease state.  
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1.1.1 Metabolism 
Metabolism involves the multitude of complex biochemical processes that occur in living 
cells in order to maintain cellular activities [2]. These processes include essential reactions 
that provide the cell with adenosine triphosphate as an energy source and synthesis of 
molecules that are required for the structure and function of the cell. Every reaction is a 
component of specific metabolic pathways that depend on enzymes that metabolize 
substrates to other molecules. The consequences of interference in a normal enzymatic or 
metabolic pathway vary in degree depending upon the position in the pathway. An IEM 
often causes a change in a specific metabolic pathway. Today, one of the main goals of 
biochemistry and cell biology is to identify all of the components of the entire intracellular 
metabolism; the intracellular metabolome [10]. 
 
1.1.2 Metabolites and biomarkes 
Metabolites are small molecules such as amino acids, organic acids and sugars that are 
present in living organisms [10]. These substances are constantly involved in a range of 
essential processes in cells and most of them are products and intermediates of metabolic 
reactions. Depending on the metabolic pathway and reactions, specific metabolites are 
involved. Measurement of metabolite concentrations in body fluids is very useful because it 
reflects the intracellular processes of the organism. Therefore, the intracellular metabolites 
can reveal the regulation in an organism due to genetic modifications and environmental 
variations. The metabolites present in cells are in exchange with the cells environment, thus, 
the metabolic profile found in body fluids can reflect the intracellular metabolism and the 
transport system for metabolites in and out of the cells. This is the fundamental basis for the 
use of body fluid metabolite analysis as a diagnostic tool in IEM. Metabolites that are used in 
clinical research and diagnosis of human diseases are referred to as biomarkers. These 
biomarkers give a unique signature that can be used for diagnoses by comparing metabolic 
differences in the healthy and the diseased states [11]. For instance, identification of high 
levels of the biomarker phenylalanine, can indicate PKU [12]. 
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1.1.3 Metabolome 
The term “metabolome” includes the complete set of endogenous, low molecular mass 
(MW) metabolites in an organism or cell [13]. It is necessary to gain knowledge of the 
metabolome in addition to the genome and proteome in order to comprehend the cellular 
mechanism. However, the complexity and the large number of metabolites have made it 
challenging to measure the metabolome systematically and efficiently. Metabolome profiling 
is an approach to measure and analyze factors in biosamples such as urine or blood. Urine 
can provide biological information since deficiency of an enzyme can for instance be 
discovered by accumulation of the enzyme’s substrate in a patient sample. Therefore, a 
profile comparison between two samples that shows a clear difference between peaks 
indicates differences in metabolism.  
 
1.2 Metabolomics 
Metabolomics is the complete analysis of the whole metabolome in a given organism or 
biological sample (3) and can be divided into targeted and global metabolomics respectively. 
Targeted metabolomics is the quantitative analysis of specific metabolites that are 
associated with a specific pathway, enzyme or metabolite class [14]. Depending on the 
analyte of interest, considerations involving the sample preparation and the analytical 
method must be taken. Diagnostics for IEM, is based on targeted specific metabolites in 
which MS/MS analysis with multiple reaction monitoring, neutral loss, precursor ion scan or 
product ion scan are frequently used. However, even though targeted metabolomics is 
undoubtedly useful in many clinical applications, significant information may be missed.  
 
Metabolomics has become an important tool in clinical research of human diseases like IEM 
that provides a “snapshot” of the physiology of the specific cell of organ [12] and therefore 
allows a holistic investigation of the metabolome. Increasing research in this field can partly 
be explained by more sensitive and accurate analytical methods like MS, in addition to the 
application of chemometric software. Study of the metabolome under a given set of 
conditions can provide significant information about metabolic pathways that are not yet 
fully understood. Global metabolomics has therefore become an approach to discover 
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biomarkers that can be used to diagnose diseases, and global metabolomics experimental 
approaches will be further discussed in 1.6. 
 
To sum up, laboratory diagnostics of IEM today are based on targeted metabolomics. New 
IEM are identified as new diagnostic metabolites are described. Global metabolomics is used 
to better understand the biochemical consequences of known IEM and to identify new 
diagnostic metabolites.   
 
1.2.1 Inborn errors of metabolism 
The term IEM refers to inherited defects in metabolism and was first described by Sir 
Archibald Garrod in his address to the Royal College of Physicians in 1908 [15]. For more 
than 40 years, and still today, GC-MS has been the key instrumentation used to identify 
urinary organic acids which are essential for routine diagnosis of IEM. However, LC in 
combination with MS/MS has become increasingly important for quantitative metabolite 
screening in clinical diagnostics, due to improvements of sensitivity and specificity, when 
profiling classes of metabolites [14].  
 
 
IEM are a large group of genetic diseases, and today more than 1000 different conditions 
have been described [16]. Generally, IEM are classified into three different groups based on 
the pathophysiology: Group 1: Disorders involving complex molecules, Group 2: Disorders 
that give rise to intoxication and Group 3: Disorders involving energy metabolism [17]. 
Individually, these conditions are rare, but collectively they are common. The conditions are 
complicated, and symptoms can vary from mild to severe among the affected children. 
However, some IEM do not show any symptoms in childhood but appear later in life. The 
rates of morbidity and mortality are high and early diagnosis and treatment are essential. A 
majority of these diseases are caused by genetic mutations which affect specific enzymes 
that catalyze specific reactions. The cells in our body continually metabolize a large number 
of different substances. An IEM results in the of absence of a normal working enzyme and 
therefore affects the complex biochemical and metabolic pathways in living cells [2]. Hence 
an IEM always results in an alteration of the metabolome.  
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In a healthy state, enzymes are working properly and thereby producing metabolites 
normally. The LC chromatogram illustrated in Figure 1 shows a theoretical separation of 
compounds in a normal metabolome profile.  
 
Figure 1: The chromatogram shows a theoretical separation of the compounds in a healthy state and 
illustrates metabolism involving conversion of metabolites A, B and C with specific enzymes E1, E2 and E3.  
 
A gene mutation resulting in a defective enzyme in a metabolic pathway may result in an 
inability to metabolize one or several substances. The LC chromatogram illustrated in  
Figure 2 shows a theoretic separation of the compounds where a specific metabolite G 
accumulates as a result of deficient enzyme E6. The resulting clinical picture and treatment 
strategy depends on a number of factors including the nature of the metabolite that builds 
up, the lack of metabolite after the block and whether the IEM affects an anabolic or 
katabolic pathway.   
 
Figure 2: The chromatogram shows a theoretical separation of the compounds in a sample from a patient 
with IEM and illustrates metabolism involving conversion of metabolites E, F and G with specific enzymes 
E4, E5 and E6. An IEM may result from a defect or absence of a specific enzyme (E6) leading to 
accumulation of metabolite G and lower concentration of H.  
 
A E1 B E2 C E3 D
E E4 F E5 G E6 H
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Alternatively, a defective enzyme may result in pathological metabolites that are normally 
not present in a healthy state. The LC chromatogram illustrated in Figure 3 shows a 
theoretical separation of the compounds including the pathological metabolites X and Y that 
accumulate because K is not metabolized to L.   
 
Figure 3: The chromatogram shows a theoretical separation of the compounds in a sample from a patient 
with IEM and illustrates metabolism involving conversion of metabolites I, J and K with specific enzymes E7, 
E8 and E9. An IEM may result from a defect or absence of a specific enzyme (E9) leading to accumulation of 
the pathological metabolites X or Y, and lower concentration of L. 
In diagnostics of an IEM at the clinical level, characteristics like appearance or smell may 
suggest a particular disease. Diagnostics of IEM are seldom provided from the clinical picture 
alone; clinical symptoms are diverse. Many IEM are differential diagnosis to non-IEM 
diseases. Laboratory analysis of biological fluids that reflect the body’s metabolism has 
therefore become an important tool for diagnosis of IEM. In a diagnostic lab, IEM can be 
diagnosed at three levels: the gene level, the gene products level and the metabolite level 
[16]. A general scheme for laboratory diagnosis of IEM is given in Figure 4.  
 
Figure 4: Laboratory diagnosis of an IEM is performed at three different levels: the gene level, the gene 
product level and the metabolite level.  
 
I
x
y
E7 K LJ E8 E9
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Diagnostics at the gene level is performed by mutation analysis. Commonly full blood and 
mutation analyses are performed in leukocytes. The enzyme activity can be measured. 
Diagnostic enzymology involves measurement of changes in activity of specific enzymes in 
disease to study pathological changes in body fluids, tissues and fibroblasts. Understanding 
how cells and intact organisms regulate the overall metabolism is critical to distinguish 
functionally regulated enzymes from abnormalities in order to comprehend the molecular 
basis of disease.  
 
Biochemical routine analysis provides important information at the metabolite level. Further 
examination may be performed to detect specific pathological metabolites when an IEM is 
suspected. These analyses are performed in urine, plasma or cerebrospinal fluid. The 
analyses are time-consuming, expensive, difficult to interpret, and the pre-analytical aspect 
of sample treatment is important. A suspected IEM based on clinical information can be 
strengthened or weakened after analysis of specific metabolites since the IEM metabolome 
is changed significantly compared to a healthy metabolome. Normally, laboratory 
diagnostics at the metabolite level is sufficient to start treatment of the disease. Follow up 
analysis is often performed, either by enzyme activity measurement or mutation analysis.  
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1.2.2 Nomenclature of IEM 
 
The nomenclature of IEM is closely related to the metabolomics of the specific disease. An 
IEM ending with -uria or -emia means elevated levels of specific diagnostic metabolites in 
urine or blood, respectively. The PKU disease is caused when the defective enzyme 
phenylalanine hydroxylase is not able to convert phenylalanine into tyrosine that normally is 
further catabolised to fumarate, which is an intermediate in the Krebs Cycle [18]. 
Phenylketonuria therefore means high levels of phenylketones in urine. Another example is 
Metylmalonic aciduria; a branched-chain organic aciduria caused by a deficiency of 
methylmalonyl-CoA mutase leading to elevated levels of methylmalonic acids in urine [17]. 
More examples of IEM caused by deficient enzymes resulting in specific accumulated 
metabolites are provided in Table 2. 
 
 
Table 2: Examples of IEM in which accumulation of a specific metabolite results in different symptoms. 
IEM Deficient enzyme Accumulated 
metabolite 
Main clinical findings 
 
Phenylketonuria  Phenylalanine 
hydroxylase 
Phenylalanine Progressive mental 
retardation  
Methylmalonic 
aciduria  
Methylmalonyl-CoA 
mutase 
Methylmalonyl-
CoA 
Metabolic acidosis 
Tyrosynemia type II 
 
Tyrosine amino 
transferase 
Succinylacetone Inflammation of cornea 
Medium-chain-
dehydrogenase 
(MCAD) 
deficiency  
Medium-chain-
dehydrogenase 
(β-Oxidation defect) 
Acylcarnitines; C6, 
C8, C10, C10:1 
Hypoglycemia 
Sudden infant death 
syndrome 
Maple syrup urine 
disease (MSUD) 
Brached chain 
oxo/keto acid 
dehydrogenase 
Leucine 
Isoleucine 
Valine 
Characteristic maple 
syrup odor 
Developmental delay  
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1.2.3 Metabolomics in biofluids 
Biofluids are biological fluids including tears, sweat, breast milk or sperm. In diagnostics 
plasma and urine have traditionally been used as they often reflect the healthy or diseased 
state of an individual and can easily be collected. Ever since 4000 BC smell, taste and color of 
urine have been important diagnostic markers of disease [9]. Abnormal urine color might be 
explained by medications or specific foods, but can also be caused by a pathological 
condition [19], see examples in Table 3. 
 
Table 3: Abnormal urine color can be resulting from certain medical conditions, medications and foods.  
Abnormal urine color Medical condition  Medication Food 
Red Sickle cell anemia Ibuprofen Blackberries 
Blue or green Blue diaper syndrome Methylene blue Herbicides 
Brown Hemolytic anemia Aceptaminophen 
overdose 
Fava beans 
White Proteinuria - - 
Black Alcaptonuria Sorbitol - 
 
 
On the molecular level, plasma and urine provide complementary information about the 
metabolic state of an organism [20]. Plasma gives an instantaneous snapshot of metabolites 
from when the sample was taken, whereas urine represents an average picture of polar 
metabolites that are excreted in inconsistent amounts according to the homeostatic control. 
Concentration, solubility and stability are important considerations of the analyte while the 
complexity of the matrix is equally important. Generally, the concentration of the analyte in 
plasma is low and the amount of sample available is limited. In urine the concentration of 
both analyte and interfering compounds is often high. Sample preparation for lab diagnostics 
should be selective and reproducible, and the analytical method of detection should be 
specific.  
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In order to achieve a holistic knowledge of human biology an ultimate starting point for 
investigation of metabolome variation is to quantify all metabolites in a biofluid [21]. 
Detected deviation in the metabolome could be caused by biological variation, but possibly 
also experimental variation. Sample collection, storage, freeze-thaw cycles and inter-
individual biological variation due to physiological and environmental factors should 
therefore be taken into account. Sample preparation in global metabolomics for unbiased 
detection of a large diversity of metabolites in body fluids should be unselective, simple and 
fast, with a minimal number of steps, reproducible and potentially including a metabolism-
quenching step [22]. Sampling time (random vs. timed, vs. 24-h), urine volume correction, 
dilution and pH adjustments should also be considered.  
 
The concentration of compounds in a urine sample is dependent on the urine volume. 
Creatinine is a breakdown product in the muscle which is excreted over a 24 hour period and 
is therefore often used as a standard correcting for dilution of the sample. In order to make 
up for different urine concentration in patients, diagnostic laboratory normalize urine 
samples by using creatinine as a reference for quantitation of diagnostic metabolites by 
measuring the metabolite/creatinine ratio in a sample. In addition, there are several 
approaches regarding normalization for different analytical methods. Commonly, 
standardized dilution (e.g. 1+9) or dilution according to concentration of creatinine is 
performed. Even though dilution of urine possibly results in decrease in ion suppression, 
urine samples are at times preferred undiluted if the analyte of interest is present in low 
concentration. 
 
1.2.4 Dietary effect of the metabolome  
 
Metabolomics in biofluids is highly dependent on intake of different foods and drinks. 
Lloyd et. al. propose a MS method for identification of urinary metabolites after 
consumption of specific foods, and thereby illustrates an example of a strategy for 
identifying effects of dietary exposure using MS and metabolomics [23]. In this study, a 
systematic experiment for investigation of the dietary effect on the urinary metabolome in a 
healthy population is examined.  
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1.3 Laboratory diagnosis of IEM in Norway  
Laboratory diagnosis of IEM is performed in the targeted approach based on measurement 
of specific diagnostic metabolites. Already in 1934, when the Norwegian biochemist 
Professor Asbjørn Følling examined two children with severe developmental delays, urine 
odor and decreased skin pigmentation, the first screening was performed [24]. Følling 
discovered excess amounts of phenylketone that is a by-product of phenylalanine. The 
observations indicated that the children were suffering from a disease known today as PKU. 
A screening assay became available in 1963, when Guthrie et. al. developed a simple test 
that could be used on all infants, to identify those affected with PKU [25]. A few drops of 
blood from the 2-3 year old child spotted on an absorbent filter paper rapidly show elevated 
amounts of phenylalanine. If the test was positive, treatment was accomplished and mental 
retardation avoided. Thereby, the worldwide NBS program was established. Today more 
accurate and rapid methods, such as MS/MS, LC-MS and gas chromatography mass 
spectrometry (GC-MS) have replaced the early screening for amino acids, and the NBS 
samples are collected 2-3 days after birth. Laboratory diagnosis of IEM in Norway is 
performed at two different laboratories, one doing NBS and the other carrying out the 
biochemical diagnostics. 
 
1.3.1 Newborn screening for IEM 
NBS procedures are performed with the intention of revealing genetic disorders. The 
Norwegian Directorate of Health suggests specific newborn screening criteria [26] according 
to World Health Organization (WHO) principles and decides which of the IEM should be 
included in the screening. There is a balance regarding what analysis should be included in 
the screening. On the one hand the NBS should promote better health and life quality for the 
children affected by IEM. On the other hand, protection of newborns and parents from 
unnecessary concerns about disease should be avoided, since expansion of screening leads 
to an increase in false positive results. Costs per analysis, advanced analysis equipment and 
the requirement of a competent staff are also important considerations. In 2012 the list of 
diseases included in NBS in Norway was dramatically expanded from 2 to 23 different inborn 
diseases, of which 21 are IEM. The aim of newborn screening is therefore to detect inborn 
diseases at an early stage in order to introduce preventive measures and to begin necessary 
treatment.   
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NBS criteria are listed below: 
1. There is a serious disease 
2. There is an effective treatment against the most serious symptoms. 
3. The effect of treatment increases when performed at an early stage. 
4. The disease can not be detected at birth without a specific screening. 
5. There is a satisfactory test for the specific disease with high specificity and sensitivity and 
low rate false positive results. 
6. The cost of screening shall be lower than the cost of treating someone with a fully 
developed disease.  
 
1.3.2 Biochemical diagnosis of IEM 
 
The Section of Inborn Errors of Metabolism at the Dept. of Medical Biochemistry at Oslo 
University Hospital, Rikshospitalet is the National Resource Centre for laboratory diagnosis of 
IEM in Norway. Biochemical diagnosis of IEM is performed on newborns with positive 
screening results in any of the 21 diseases. In addition, samples and clinical information from 
patients with symptoms indicating an IEM are sent to MBK and specific analysis is performed 
based on this information. The large diversity of important diagnostic analysis is illustrated in 
Table 4. 
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Table 4: Laboratory diagnosis of IEM performed at MBK, Rikshospitalet by detection of specific analytes 
in different body fluids illustrates the broad range of analytical techniques utilized.  
Analyte Method / technique Matrix 
Amino acids quantitative Amino acid analyzator Urine 
Plasma 
Acylcarnitines  LC-MS/MS Plasma 
Serum 
Amino acids  Paper chromatography Urine 
Carnitine, total and free LC-MS/MS Urine 
Carbohydrate-deficient transferrin Capillary electrophoresis 
(CE) 
Serum 
Creatine and guanidinoacetate  LC-MS/MS Urine 
Plasma 
Cysteine in leukocytes Cysteine binding assay Blood 
7-dehydrocholesterol   GC-MS Serum 
Metylmalonic acid LC-MS/MS Serum 
Mucopolysaccharides  Thin layer chromatography Urine 
Organic acids  GC-MS Urine 
Orotic acid MS/MS Urine 
Oxalic acid MS/MS Urine 
Purines and Pyrimidines   LC-MS Urine 
Sugars  Sugar paper 
chromatography 
Urine 
Very long chain fatty acid and phytanic 
acid 
GC-MS Serum 
Enzyme activity Mutation analysis Erythrocytes 
Fibroblasts 
Leukocytes 
Creatinine, glucose, urine acid, glycerol, 
nitrate, pH, ketones, leukocytes, 
nitroprussid   
Standard clinical chemistry 
Urine stix 
Urine  
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Class specific analysis refers to the measurement of classes of components that produces a 
common set of fragments. A well known example is the analysis of acylcarnitines by MS/MS. 
Since a complex mixture can contain thousands of molecules and different molecules may 
share the same MW, a secondary separation system like LC or GC is often used. MS/MS 
enables control of the formation of molecular and fragment ions. Particular compound 
classes can be measured specifically, since certain classes share common fragment classes 
with fragment ions. Details on the currently used method for acylcarnitine analysis can be 
found in appendix (chapter 8.2). Class specific analysis is of great importance in laboratory 
diagnostics as it provides reliable quantitative data on important diagnostic markers. 
However, this targeted approach only provides information about the analytes of interest 
and will not reveal potential unknown metabolites.         
1.4 Reversed phase liquid chromatography 
LC is a separation technique where compounds migrate through a column with different 
velocities due to different equilibriums between a solid stationary phase (SP) and the liquid 
mobile phase (MP). Depending on the analyte of interest a broad range of column SP 
chemistries can be selected and C18 is the most commonly used. The MP in reversed phase 
(RP) is polar and consists of an aqueous and organic solvent with a pH adjustment additive, 
e.g. a buffer. Reversed phase chromatography is the most frequently used separation 
principle where the SP is nonpolar and eluent strength increases with less polar solvent [27].  
 
1.4.1 Column dimension  
Down-scaling the inner diameter (ID) of the column will lead to an increased signal-to-noise 
(S/N) ratio with concentration sensitive detectors, such as ESI MS, since dilution of the 
analyte(s) will decrease [28]. Other benefits compared to larger ID columns are lower 
consumption of MP that is friendlier towards the environment and the economy. In addition, 
small-bore columns do not require flow splitting before the mass spectrometer. The 
disadvantages of miniaturization are critical dead volumes, risk of clogging and a less rugged 
system. In this study narrow bore columns (ID 2 mm) were used. 
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1.5 Mass spectrometry  
The principle of MS is; to generate ions in gas phase, to separate these ions by their mass to 
charge ratio (m/z) and to detect the ions qualitatively and quantitatively according to their 
m/z and abundances [29]. The mass spectrometer consisting of an ion source, a mass 
analyzer and a detector provides both qualitative and quantitative information about the 
composition of both organic and inorganic compounds in complex samples. Information 
about isotope ratios provides information about characteristic isotopic pattern like Cl and Br, 
which may be used to identify unknown compounds. A mass spectrum is a representation of 
signal intensity versus m/z ratio versus intensity in a sample that has successfully been 
transferred into ions in gas phase. The advantages of MS are identification and quantification 
of a broad range of MW analytes, detection levels from ng/mL to pg/mL and structural 
information [14]. However, the disadvantage of using MS is the inability to separate isobaric 
or isomeric compounds. Using ESI MS, possible ion suppression is also a well known 
weakness. 
1.5.1 Ionization techniques  
There are several ionization techniques including the most commonly used ionization 
techniques ESI, electron ionization (EI), atmospheric pressure chemical ionisation (APCI) and 
matrix assisted laser desorption ionisation. Today, the LC-MS technology is based on 
ionization techniques developed by Fenn et al. in the 1980s [30]. Among the atmospheric 
pressure ionization techniques, ESI has a higher dynamic range (polarity and mass range) 
than APCI and is widely used in applications for proteomics, drugs and metabolites. In ESI the 
ionization technique is based on formation of gas phase of ions from the ions in liquid 
between the LC capillary and the MS inlet. This ionization process can be divided into three 
major steps, a) production of charged droplets at the capillary tip, b) evaporation of charged 
droplets results in higher density of charges in the droplet, c) production of gas phase ions 
[31]. The ionization process is illustrated in Figure 5. 
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Figure 5: Ions in gas phase are formed in the electrospray interface for MS. Charged droplets produced at 
the capillary tip is evaporated bringing the charges closer together until free ions are released.  
 
ESI is convenient for coupling to LC and has become a powerful tool for analyzing ionic and 
ionisable components. This ”soft” ionization technique, driven by an electric potential, 
results in less fragmentation than EI, where molecular ions and some fragments can be 
produced. For macromolecules multiple charges are quite common. Ion suppression is one 
of the most important challenges in ESI when there is competition for charge between co-
eluting compounds. Organic modifiers like methanol (MeOH) and acetonitrile (ACN) are 
often used, while salts with high ionic strength should be avoided as they are likely to form 
adducts, which can lead to a decrease in selectivity and sensitivity, and contamination of the 
ion source might also occur. ESI is concentration sensitive and small ID columns are 
advantageous for increased response. Degree of ionization, surface activity, hydrophobisity, 
adduct-ion stability and solvation energy also determine the response of different 
compounds.   
 
The choice of ionization mode, positive [M+H]+  or negative  [M-H]-, depends on the 
analyte(s) of interest. ESI in positive mode can effectively ionise a broad range of medium 
polar and polar molecules and is therefore the most commonly used mode in LC-MS [32]. 
Generally, most molecules more easily stabilize positive ions than negative ions. Detection of 
negative ions is obtained with less chemical background noise and less adducts formation. 
For these reasons negative ionisation generally provides higher selectivity than positive 
ionisation. In order to increase detection of different metabolites, and thereby provide a 
more holistic insight into the metabolome, APCI has been shown to provide a significant 
increase in the number of additional metabolites revealed compared to ESI [33]. Because of 
Initial droplet with ions
From capillary (3.5 kV)
Evaporation
To MS
Free ions 
 28
the large diversity in molecules, one methodology cannot cover all types of molecules and 
the different ionization techniques are therefore complementary. 
 
1.5.2 Tandem mass spectrometry 
The charged compounds in gas phase can be separated by different mass separators, like the 
quadrupole, time-of-flight (TOF), ion trap or magnetic sector, and a combination of these. In 
the following section, the instrument set up relevant to this master thesis will be described. 
The principle of the quadrupole mass filter is detection of ions with specific mass by varying 
the electric field. Typically, this mass separator consists of four parallel metal rods carrying 
both a constant voltage and a radio frequency oscillation [27]. Only ions with a particular 
m/z ratio reach stable oscillations that allow them to pass through the separator and to be 
detected, while unstable ions collide with the rods before reaching the detector. Because of 
its low cost, the quadrupole is one of the most common mass analysers. The TOF mass 
analyzer principle is separation based on accelerating all ions to identical kinetic energy. The 
ions reach a velocity which depends on their mass. Ions with different mass and the same 
energy will be separated, as light ions will reach a higher velocity than heavy ions and will 
therefore reach the detector first. In this study a mass separator of the type quadrupole 
time-of-flight (Q-TOF) was used and a schematic illustration is provided in Figure 6. 
 
Figure 6: A schematic illustration of a MS/MS Q-TOF mass separator used in this study, consisting of a 
quadrupole , a hexapole collision cell and a TOF to produce spectrum.   
Ions from source
Collision cell
Q2
Detector
Reflectron
Quadrupole
Mass filter
Time-of-flight
Repeller
Flight tube
Quadrupole
Octapole 1 Octapole 2
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1.5.3 Data processing  
Molecular feature extraction (MFE) is one of the data mining algorithms available in the 
software MassHunter (Agilent Technologies). MFE, which is the method of choice for 
untargeted discovery workflows that operate on single mass spectrometry (MS1) data to find 
unique compounds, includes the following: 1. Raw data appears as a 3-dimensional array 
between retention time (tR ), m/z and abundance. 2. Background noise is removed. 3. Search 
for features with common elution profiler including adducts, isotope clusters, dimers and 
charge states. Method parameters can be adjusted according to the desirable data. The 
"extraction peak filters" is an adjustable parameter that depends on the chemical noise level 
in the spectrum. The compound filter is a threshold for absolute height (in counts) set 
according to the chromatogram level. Different ion species can be included or excluded 
depending on the probability of these ions being present in the system. In this study, MFE 
was used for method development and method evaluation, and to study the intra- and inter- 
individual biological variation in metabolome affected by diet.   
 
Mass profiler professional (MPP) is a LC-MS statistical analysis software provided by Agilent 
Technologies for compound identification and biochemical pathway analysis. Principal 
component analysis (PCA) is based on capturing variance in a data set using vectors of the 
first three principal components [34]. Samples within one experimental condition should be 
more similar than those from different conditions, and is therefore expected to group closer 
together. In this study, PCA was performed to examine how the metabolome in healthy 
volunteers alters with different diet intake.  
 
1.6 Global metabolomics 
 
 
Global metabolomics, also referred to as untargeted metabolomics, is measurement of a 
large number of metabolites in an unbiased approach [14]. In other words, untargeted 
metabolomics is the study of the metabolome with the aim to quantify all the metabolites 
detected in one sample. Unlike targeted metabolomics, where specific metabolites are 
analyzed, untargeted metabolomics is used to capture as much information possible about 
all metabolites in the sample. Since untargeted metabolomics involves the study of all 
metabolites in one sample, it is important to evaluate sample collection, sample preparation, 
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chromatographic procedure and data processing [35] reduce sample pretreatment to a 
minimum, in order to avoid exclusion of metabolites.  
 
A typical metabolomics experimental set-up for biomarker discovery of an IEM is shown in 
Figure 7.  This approach can be used to discover now biomarkers for known diseases, or to 
find new IEM by identification of diagnostic metabolites in samples from patients suspected 
to have an IEM, but where no diagnostic metabolite is identified using the routine methods. 
The samples are processed depending on the chosen technology for separation, for instance 
LC-MS, GC-MS or Nuclear Magnetic Resonance (NMR). Data from patients and a healthy 
control group is compared to identify differences. The definition of a normal metabolome 
must rely on the measurement of the global metabolome in an adequate healthy control 
group. The importance of obtaining normal data must be emphasized, because the 
metabolome will vary between healthy individuals. Identification of an “abnormal peak” 
might be either a “normal” metabolite in an abnormal concentration (G in Figure 2), or a 
pathological metabolite (X and Y in Figure 3).  
 
 
 
Figure 7: A typical global metabolomics experimental setup for potential biomarker discovery, adapted from 
[11]. 
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For global metabolomics, method development should be examined to find the most 
optimal conditions for a complete analytical system, including analytical columns, MP etc. 
Kloos et. al. tested different column chemistries for fast urinary metabolic profiling by LC TOF 
MS [36]. Performance of RP LC vs. hydrophilic interaction liquid chromatography (HILIC) 
materials were examined in combination in a non-targeted manner. For the RP columns, 
different MP conditions were examined and the number of detected molecular features 
when eluting with MeOH compared to ACN minimal. Kloos et. al. recommend the use of 
HILIC for urinary metabolomic profiling with high throughput. The PFP column gave the best 
results of three different RP columns with regards to the number of molecular features. 
Furthermore, this column was chosen as it provides π-π-interactions in addition to classic 
C18-RPLC interactions with analytes. Roux et. al. conclude that a minimum of two different 
complementary chromatographic methods should be used for urinary metabolomics in order 
to discriminate between isomers [37]. LC separation was performed by a C18 (150 x 2.1 mm, 
1.9 μm) column combined with LC separation by a pentaflourphenylpropyl (PFPP) (250 x 2.1 
mm, 5.0 μm) column, to separate a broad range of different chemical families such as 
acylcarnitines, organic acids and amino acids.  
 
 
1.7 Aim of study 
The primary goal of this study was to develop a robust and reproducible LC Q-TOF MS 
method with positive ionization, useful for untargeted urine metabolomics. The method 
developed should also be applicable to negative ionization which was studied by Siv M. 
Løvoll [1]. The method will be validated and used to study the normal metabolome for intra- 
and inter- individual biological variation. During the study, a black urine sample from a 
patient, suitable for investigation and identification at Section for Inborn Errors of 
Metabolism, was used as a spotlight project. Several methods were utilized in order to 
identify the compound responsible for the black color.  
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2 Experimental 
2.1 Materials and methods  
Chemicals 
Type I water was obtained from Milli-Q ultrapure water purification system (Millipore, 
Billerica, MA, US) was used to prepare standards and MP in combination with high purity 
MeOH and ACN was obtained from Merck (MeOH, Dramstadt, Germany), high purity acetic 
acid (AA) and formic acid (FA) obtained from Sigma (Fluka, Sigma Aldrich, Dramstadt, 
Germany). Ammonium acetate was obtained from Riedel-DeHaen (Seelze, Germany) to 
investigate the unknown compound in black urine, potassiumhydroxide, 5-aminosalicyclic 
acid (5-ASA) and homogentisic acid obtained from Sigma were used. 
 
A standard mixture called magic mix was prepared including the following chemicals: 3-
hydroxybutyrate, L-allo-isoleucine, parahydroxyfenylactate, creatinine and succinylacetone 
were obtained from Sigma. Hippuric acid, citric acid and deoxyadenosine was obtained from 
Merck. The origin of hexanoylglycine is unknown.  
 
Artificial urine was prepared including the following chemicals: potassiumsulfate and 
dipotassiumhydrogenphosphate obtained from Merck, ureic acid and potassiumdihydrogen 
phosphate was obtained from VWR (West Chester, PE, US), potassiumchloride was obtained 
from Chemi-Teknik AS (Oslo, Norway) and magnesium sulfate was obtained from Sigma.  
 
MS reference ion solution and tuning mix were obtained from Agilent Technologies (St. 
Clara, CA, USA) 
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2.2 Samples 
2.2.1 Control and standards 
Batch urine was prepared as a long term quality control by collecting urine from healthy 
volunteers and was pooled in order to increase the complexity of the urine.  Furthermore 
the sample was aliquoted and stored at -70 °C, until the day of analysis.        
  
The magic mix was prepared based on compounds with a broad spectrum of physio-chemical 
properties reflecting the diversity of metabolites found in urine. A selection of 9 different 
endogenous compounds of interest in lab diagnosis of IEM was prepared in water and 
artificial urine respectively, concentration of creatinine 5.0 mmol/L and the remaining 0.5 
mmol/L. Artificial urine dissolved in water used for evaluation of matrix effects was prepared 
using a mixture of different salts, made according to a recipe provided by Oslo University 
Hospital, see appendix (chapter 8.3).  
 
2.2.2 Urine collection and preparation  
Urine samples used for investigation of the metabolome were collected by taking midstream 
of the first morning urine from healthy volunteers and were stored at -70°C until the day of 
analysis. For RPLC separation urine samples were thawed and filtered through a 0.22 μm 
cellulose acetate spin filter (Agilent Technologies) at 14800 rpm, at 4 °C for 5 min. 
 
 
2.2.3 Columns  
 
The various RP columns examined were Pursuit XR’s Diphenyl and Polaris Ether obtained 
from Matriks AS (Oslo, Norway), Kinetex C18 (Phenomenex), Atlantis C18 T3 obtained from 
Waters, C18 H2o (Fortis) obtained from Holger Teknologi AS, C18 PFP both 150 and 250 mm 
ACE Technologies (Advanced Chromatography Technologies, Aberdeen, Scotland) used with 
C18 PFP guard cartridge obtained from TeknoLab AS (Kolbotn, Norway), see Table 5. 
Additionally, a zwitterionic (ZIC) HILIC (Syncrosis 150 x 2.1 mm, 5 μm. 100 Å) (Thermo 
Scientific) was examined. All columns except C18 PFP were examined using an online 0.5 μm 
prefilter (Phenomenex).  
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Table 5: Analytical RP columns examined during method development 
Column 
 
Column 
length 
(mm) 
Column 
diameter 
(mm) 
Particle 
Size (μm) 
Pore 
Size (Å) 
Surface area 
(m2/g) 
Carbon 
load (%) 
Pursuit XR’s 
C18 
Diphenyl 
250 2.0 3 100 440 14.6 
Polaris C 18 
Ether 
250 2.0 3 180 200 12.1 
Kinetex C18 100 2.1 2.6 100 200 12.0 
Atlantis T3 
C18 Polar 
endcapped 
150 2.1 3 100 330 14.0 
Fortis H2o 
C18 Polar 
endcapped 
150 2.1 3 120 380 18.0 
ACE C18 PFP 150 2.1 3 100 300 14.3 
ACE C18PFP 250 2.1 3 100 300 14.3 
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2.3 Liquid chromatography and mass spectrometry 
 
The LC-MS analyses were performed using an Agilent 1200 series LC (Agilent Technologies) 
coupled to a tandem MS Q-TOF 6520 series (Agilent Technologies) fitted with an ESI source 
operating in positive mode. The LC-pump was operated at a flow rate of150 μL/min. The MP 
consisted of H2O and MeOH both containing 0.1 % of AA, and gradient separation was 
performed according to Table 6. 
 
Table 6: Gradient elution A: H2O + 0.1 % AA and B: MeOH + 0.1% AA 
Time (min) % A:  
100 % H2O + 0.1 % AA 
% B: 
100 % MeOH+ 0.1 % AA 
0 98 2 
10 98 2 
50 0 100 
55 0 100 
55.1 98 2 
65 98 2 
 
The separations were performed on an ACE PFP C18 (250 x 2.1mm, 3 μm) column particles 
equipped with a C18 PFP precolumn (lenght 1.0 cm). The LC system was equipped with an 8 
μL loop and 8.0 μL was injected. The software used was MassHunter version B.04.00 (Agilent 
Technologies). Before every analysis the MS was calibrated using a calibration solution 
provided by the manufacturer and the mass accuracy was within the range of 2 ppm. 
Reference masses obtained from manufacturer were introduced to the MS during all analysis 
and the raw data are automatically calibrated in MassHunter Workstation Software Version 
B.04.00 (Agilent Technologies). All analyses were performed at ambient temperatures.  
 
Ionization was performed in positive mode with capillary- and skimmer voltage set on 3500 
V and 65 V respectively. Nebulizer gas and drying gas was set at 30 psig and 5 L/min 
respectively. MS 1 was employed at low dynamic range m/z 100-1700. 
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2.4 Data processing 
In this study the MFE parameters were set based on one batch urine, and within the 
manufacturers’ recommendations according to Table 7. 
 
Table 7: MFE parameters for data processing for determining the total number of molecular features 
detected 
Parameter Setting 
Peak filters ≥ 500 counts 
Compound filters (absolute height) ≥ 5000 counts 
Allowed ion species [H +], [Na +] and [NH4 
+] 
 
 
Data from urine samples from investigation of diet effect were processed in MPP 
MassHunter version B.02.01 (Agilent Technologies) 
 
3 Results and discussion 
3.1 Method development 
A robust method for untargeted metabolomics in healthy human urine using LC Q-TOF MS 
with ESI in positive mode was to be developed. Generally, positive ionization is the most 
commonly used ionization technique while negative ionization is often preferred for 
metabolites that are cannot easily be ionized in positive mode [38]. Since the optimal 
conditions for the two ionization modes not often are the same, the method developed must 
potentially compromise, since this thesis is one half of a study where both positive and 
negative is included. Selection of LC-column, gradient, MP and sample preparation will be 
evaluated in this study. The setup giving the highest number of molecular features for the 
batch urine will be the method of choice.  
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3.1.1 Selection of RP column 
 
To develop a sensitive and rugged RP LC tandem MS/MS method for untargeted 
metabolomics in human urine, several different analytical columns were examined. By 
comparing the number of different separated compounds in batch urine, the column 
separating the highest number was chosen.  
 
LC separation was performed on 7 different RP analytical columns with different properties, 
see Table 5. In addition one HILIC column with separation conditions was examined. The 
choice of column chemistries and diameter were done in collaboration with the application 
specialists for clinical application at the different column manufacturer.  
Batch urine was used as a real biological matrix to monitor the total number of different 
molecular features separated by each column, and thereby compare column performance. 
Injection volume used was 5.0 μL and the gradient used is shown in Table 8.  
 
 
Table 8: Gradient elution A: H2O + 0.1 % FA and B: MeOH + 0.1% FA 
    Time (min) % A: 
100 % H2O + 0.1 % FA 
% B: 
100 % MeOH + 0.1 % FA 
0 98 2 
10 98 2 
40 50 50 
50 10 90 
54 98 2 
64 98 2 
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A Magic mix of 9 known endogenous compounds, see Figure 8, dissolved in water was 
injected onto the 7 different RP columns to compare the separation capability of the 
columns. The compounds of the magic mix are well known is the diagnostic laboratory work 
of IEM. The biological source of each compound in addition to diagnostic function or 
correlation to a specific IEM disorder is listed in Table 9.  
 
 
 
 
Figure 8: Structure of the 9 compounds in the Magic mix.  
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Table 9: The compounds of the Magic mix listed with biological source, in addition to biological function or 
correlation to s specific IEM disorder 
Compound Source Function / IEM disorder  
A) Creatinine Endogenous breakdown 
product from muscle 
Reflects urine dilution 
Normal constituent of urine  
B) Alloisoleucine Exogenous, branched 
chained amino acid from diet 
(protein) 
Branched chain organic aciduria  
Eg. MSUD 
C) Citric acid Endogenous (tricarboxylic 
acid cycle) and exogenous 
Metabolic acidosis. Relevant for lab 
diagnosis of crystal growth inhibitor.  
D) Deoxyadenosine DNA nucleoside A Purine pyrimidine metabolism 
deficiency 
E) Succinylacetone Endogenous, breakdown 
product of tyrosine 
metabolism 
Patognomonisk Tyrosynemia type I 
F) Parahydroxyphenyl  
lactic acid 
Endogenous breakdown 
product from tyrosine 
metabolism 
Disorder of tyrosine metabolism, Eg. 
Tyrosynemia 
G) Hippuric acid Endogenous. Concentration 
increase with consumption 
of phenolic compounds 
Organic aciduria 
Normal constituent of urine 
H) Hexanoylglycine Endogenous. Metabolite for 
fatty acid metabolism 
Fatty acid oxidation disorder  
Eg. MCAD  
I) 3-hydroxybutyric acid Ketone body synthesized in 
liver 
Branched chain organic aciduria 
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The separation of compounds in the Magic mix with compound A-H was examined for 7 
different RP columns, see Figure 9. Each compound were separated by all 7 columns in 
identical order, except for citric acid (compound C) eluting both prior to and after 
alloisoleucine (compound B). The largest difference in elution time was approximately 15 
minutes between Kinetex C18 and Pursuit XR’s Diphenyl.  
 
 
Figure 9: Total ion chromatograms (TIC) of compounds in Magic mix separated on 7 RP columns with 
gradient in Table 8. 5.0 uL were injected. Detection was carried out in positive mode with mass range m/z 
50-2800. The compounds injected were: A. Creatinine (5 mmol/L); B. Alloisoleucine (0.5 mmol/L) ; C. Citric 
acid (0.5mmol/L); D. Deoxyadenosine (0.5 mmol/L); E. Succinylacetone (0.5 mmol/L) ;F. Parahydroxyphenyl 
lactic acid (0.5 mmol/L); G. Hippuric acid (0.5 mmol/L) and H. Hexanoylglycine (0.5 mmol/L), see Figure 9. 
The columns examines were: 1: Pursuit XR’s Diphenyl; 2. Polaris C18 Ether; 3. Kinetex C18; 4. Atlantis T3 
C18; 5. Fortis H2o C18; 6. ACE C18 PFP (150 mm) and 7. ACE C18 PFP (250 mm), see Table 5.  
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Succinylacetone (compound E) was separated with all columns, although in a very broad 
peak in Figure 10. 
 
 
 
Figure 10: Chromatogram (EIC) of succinylacetone (E)(0.5 mmol/L) separated on an ACE (250 x 2.1 mm, 3 μm) 
column with the gradient described in Table 8. 5.0 μL was injected. Detection was carried out in positive 
mode with m/z 50-2800.  
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All columns were examined using the same chromatographic conditions to detect the 
highest number of molecular features in the batch urine. The ACE C18 PFP (250 x 2.1 mm, 3 
μm) column (marked green in Figure 10) separated the most different molecular features in 
batch urine, see Figure 11.  
 
Figure 11: The diagram provides the total numbers of molecular features detected in batch urine by 7 
different RP columns, see Table 5. Data were collected in the mass range m/z  50-2800. MFE filter was 
used according to parameters in Table 7.  
 
The ACE C18 PFP (250 x 2.1 mm, 3 μm) column provided the highest number in both positive 
and negative ionization [1] and was therefore chosen for further metabolomics studies in 
urine. Since the Fortis polar endcapped C18 (150 mm) column detected a higher number of 
molecular features than ACE C18 PFP (150 x 2.1 mm, 3 um) column suggests that a longer 
Fortis column also could have been examines. In addition, all columns were tested with 
identical chromatographic conditions and it could be argued that each column should be 
optimized separately to provide best possible separation. However, our aim was to create an 
LC-MS method providing the highest number of detectable molecular features of urinary 
compounds and conclusion will be drawn based on the experimental approach. Further 
optimization with the selected column was performed during method development.  
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3.1.1.1 Evaluation of HILIC 
HILIC, which is suitable for separation of polar compounds, has good potential for 
metabolomics in urine. Zang et. al. [39] evaluated RP, aqueous normal phase and HILIC with 
Orbitrap MS for metabolomic studies of human urine. According to this study ZIC-HILIC was 
able to detect most unique m/z features (33 %) in positive ionization and RP detected the 
fewest (6%). HILIC provided the best separation of isomers and best repeatability in their 
study. 
 
In the present study a ZIC-HILIC Syncrosis (150 x 2.1 mm, 5 μm) column was examined based 
on method used by Zhang et. al. [39] for metabolomics. The gradient shown in Table 10 was 
used and the resulting chromatogram is shown in Figure 12. 
 
Table 10: Gradient elution A: H2O + 0.1 % FA and B: ACN + 0.1 % FA 
Time (min) % A: 
100 % H2O + 0.1 % FA 
% B: 
100 % ACN + 0.1 % FA 
0 20 80 
30 80 20 
35 95 5 
45 20 80 
 
 
Figure 12: Chromatogram (TIC) of batch urine separated on a ZIC-HILIC Syncrosis (150 x 2.1 mm, 5 μm) 
column with the gradient shown in Table 10. Detection was carried out in positive mode in mass range m/z 
50-2800. The batch urine was diluted (5x) with ACN and 5.0 μL was injected.  
 44
 
The reason for the poor chromatography using the ZIC-HILIC column could be many. First, 
there might have been water in the needle seat. The requirements of the system to dilute 
the urine sample in organic solvent to prevent “plug elution” is not ideal in this study, as 
compounds present in low concentration may not been detected after dilution (5x). Because 
of the poor chromatography obtained, further studies were not carried out with the HILIC 
column.  
 
3.1.2 Mobile phase 
Organic solvents used in MP in ESI MS/MS may be associated with ion suppression and 
adduct formation. Depending on the analyte of interest MP, additives and pH among others 
can be optimized in order to increase the formation of ions in the solution phase, and 
thereby improve sensitivity of detection [40]. In this study MeOH was examined in 
combination with different additives for detection of polar metabolites in urine, since ACN 
has weaker elution strength in RP which is not optimal for polar compounds separated on 
RP.  
 
MeOH in combination with 0.1 % FA and 0.1 % AA resulted in 3801 and 5445 molecular 
features respectively, and AA was therefore chosen for further studies. Ammonium acetate 
(10 mM) was also tested but did not result match the number of molecular features 
detected with AA.  
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3.1.3 Gradient profile evaluation  
In RP chromatography retention of analytes of interest in addition to the complexity of the 
sample, influence the optimal gradient profile since polar compounds will elute earlier than 
non-polar compounds. In study four gradient profiles were investigated to possibly increase 
the number of molecular features, see Figure 13. All of the examined profiles were 
approximately one hour long to possibly increase separation. 
 
 
 
Figure 13: The figure shows four gradient profiles tested. 5.0 μL of batch urine was injected in triplicate and 
separated on an ACE C18 PFP (250 x 2.1 mm, 3 μm) column. 
 
MFE was performed according to Table 7 in time intervals based on the slope of gradient no 
1. The mean value of number of molecular features detected after injection of batch urine in 
triplicate for gradient profile 1-4 are provided in Table 12.  
 
Table 12:  The number of molecular features detected (CV %) in batch urine by using four the gradient 1-4, 
see Figure 13.  
Gradient profiles 1-4 
Interval (min) 
1 2 3 4 
0-10 1352 (0.4%) 1306 (1.3%) 1293 (1.4%) 1406 (0.3%) 
 10-40 2341 (1.0%) 2342 (2.9%) 2779 (1.1%) 3545 (0.7%) 
40-50 1150 (2.2%) 1159 (1.7%) 1520 (0.4%) 1584 (4.5%) 
50-54 325 (2.6%) 747 (3.2%) 365 (1.6%) 391 (5.1%) 
54-65 487 (4.8%) 1014 (4.4%) 320 (23.9%) 751 (7.4%) 
Total 5655 6568 6277 7678 
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From the number of molecular features it was concluded that profile number four was most 
suitable for further the aim of this study. The performance of the column was evaluated to 
gain a better understanding of how the analytes spread throughout the gradient. TIC of 
batch urine with gradient profile no 4 is shown see Figure 14.   
 
 
 
Figure 14: Chromatogram (TIC) of batch urine separated on a C18 PFP (250 x 2.1 mm, 3 μm) column with the 
gradient described in Table 6. Detection was carried out in positive mode and 5.0 μL was injected. The data 
were collected in the mass range m/z 100-1700. The dotted line represents the used gradient. MFE was used 
according to Table 7.  
 
The high number of molecular features found throughout the gradient shown in the TIC 
above demonstrates the usefulness of utilizing an hour long gradient.  
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3.1.4 Sample preparation  
 
Ideally, no sample preparation should be performed in metabolomics because of the 
possibility of handling the samples differently and eventual loss of analytes. In addition, 
shorter time consumption is always preferable. However, advanced analytical technologies 
require a minimum of sample preparation for instrument maintenance. In this study, 
different sample preparation filters were tested to evaluate if the filter added compounds to 
the sample. Polyvinylidene flouride (PVDF) 0.22 μm syringe filter (Millipore) was tested, but 
eliminated due to the unpractical filtration technique. Further, two different spin filters, 
suggested by manufacturers useful for metabolomics is urine, were tested: Cellulose acetate 
0.22 μm spin filter (Agilent Technologies) and PVDF 0.22 μm spin filter (Millipore).   
 
From the results (not shown), it was observed a small increase of approximately 50 features, 
between filtrated- and un-filtrated H2O, and the increase was practically identical. For global 
metabolomic studies, it is not ideal to use filers that add compounds to the filter. However, if 
the identical features are added to each sample, there might not be a difficulty after all. 
Nevertheless, this emphasizes the importance of sufficient evaluation prior to a study.     
For the purposes of this work, Cellulose acetate 0.22 μm spin filter (Agilent Technologies) 
was the filter of choice mainly due to economic considerations. 
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3.2 Effect of different injection volume  
 
In diagnostics injection volumes is dependent on the concentration of the analyte of interest 
and the availability of sample. However, in global metabolomics detecting as many 
molecular features as possible it is not obvious what injection volume would provide most 
compounds. One advantage of urine analyses is the availability of large sample volumes. The 
developed method uses 8.0 μL, but effect of smaller injection volumes was tested to 
investigate possible decrease in ion suppression. Three different injection volumes tested 
were 0.1 μL, 5.0 μL and 8.0 μL and the number detected features were compared. The TICs 
are provided in Figure 15.  
 
 
Figure 15: Chromatogram (TIC) of batch urine separated on ACE C18 PFP (250 x 2.1 mm, 3 μm) column for 
examination of varying the injecting volume. 0.1 μL, 5.0 μL and 8.0 μL were injected onto the column and 
detection by Q-TOF was performed in positive mode. Used gradient is provided in Table 8. The data were 
collected in the mass range m/z 100-1700. 
 
The highest number of molecular features was found in the largest injection volume, which 
indicates an up concentration of compounds present in low concentration. Therefore, 
increasing of injection volume does not seem to become a larger challenge when it comes to 
ion suppression, which can be due to the long gradient time of approximately one hour. 
Based on the number of molecular features 8.0 μL will be used further in this study. 
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3.3 Studies of possible matrix effects 
Ion suppression is one of the main challenges in ESI MS, particularly regarding complex 
samples. Dilution of urine sample could potentially result in less degree of ion suppression. 
In this study, investigation of possible ion suppression was performed by diluting urine 
samples based on concentration of creatinine. The number of molecular features extracted 
for four different urine samples collected from one healthy volunteer and the respective 
diluted urines is shown in Table 15. 
 
Table 15:  Urine sample 1 with creatinine concentration of 20 mmol/L was diluted to 13 mmol/L and 7 
mmol/L and 0.6 mmol/L respectively. Urine sample 2 with creatinine concentration of 13 mmol/L was 
diluted to 7 mmol/L and 0.6 mmol/L respectively. Urine sample 3 with creatinine concentration of 20 
mmol/L was diluted to 13 mmol/L and 7 mmol/L and 0.6 mmol/L respectively. Urine sample 4 with 
creatinine concentration of 0.6 mmol/L was not diluted. Injection volume was 5.0 μL and gradient used 
is shown in Table 8. The data were collected in the mass range m/z 100-1700 and the MFE was 
performed according to Table 7. 
Sample Dilution 
factor (DF) 
Creatinine concentration 
(mmol/L) 
# molecular features 
1 - 20.3 7538 
1 1.5 13.1 6519 
1 2.9 6.9 5529 
1 33.8 0.6 1886 
2 - 13.1 6514 
2 1.9 6.9 5558 
2 21.8 0.6 1713 
3 - 6.9 5763 
3 11.5 0.6 1933 
4 - 0.6 2282 
 
Dilution resulted in a decrease in total number of molecular features in sample 1-3, which 
suggests that ion suppression might not be significant for this method. The numbers of 
molecular features detected in different samples with matching creatinine concentration are 
quite similar. However, since these samples are not collected identically, the total number 
only gives a certain idea.  
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3.3.1 Effect of urine dilution on molecular features 
 
Compound with m/z 103.03 eluting at 5 minutes was selected randomly and extracted from 
urine sample nr 1, with creatinine concentration of 20, 13 and 7 mmol/L respectively, see 
Figure 16. Peak are and height are shown in Table 16. The compound could not be detected 
in the urine diluted to creatinine concentration of 0.6 (mmol/L). 
 
Figure 16: Chromatogram (EIC) of compound m/z  103.03 in the identical urine sample diluted to different 
concentration of creatinine; 1 (20 mmol/L), 2 (13 mmol/L) and 3 (7 mmol/L) separated on a ACE C18 PFP 
(250 x 2.1 mm, 3 μm) column with the gradient described in Table 8. Detection was carried out in positive 
mode and 5.0 μL was injected. The data were collected in the mass range m/z 100-1700. 
 
Table 16: tR, peak area and height of compound m/z 103.0 extracted from sample 1 (see Table 15) with 
creatinine concentration of 20, 13 and 6 (mmol/L).  
Sample Creatinine (mmol/L) tR of m/z 103.03 Area 
1 20 5.12 901646 
1 13 5.14 824600 
1 6 5.17 612261 
 
Although, the compound m/z 103.03 was detected in the urine sample with various dilution 
grades, the MFE filter setting determines whether the compound will be counted for a 
molecular feature. The effect of adjusting MFE filter settings will be discussed in the 
following section. 
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MFE filter settings may be adjusted based on the analytes of interested and intensity of 
background noise in the chromatogram and spectrum. Increasing the peak filter setting and 
compound filter will eliminate more peaks coming from the noise. However, increasing the 
peak filter can also potentially eliminate actual compounds.   
  
In this study, the MFE filter used have been according to Setting A in Table 17. Using these 
settings, the compound m/z 103.03 could only be detected using MFE in the samples with 
creatinine concentration of 20 and 13 mmol/L. In contrast, the same compound could not be 
detected in the sample with creatinine concentration of 6 mmol/L, until the filters were 
lowered according to Setting B.    
 
Table 17: Evaluated MFE parameters including peak filter, compound filter and allowed ion species. 
Parameter Setting A Setting B 
Peak filters ≥ 500 counts ≥ 100 counts 
Compound filters 
(absolute height) 
≥ 5000 counts ≥ 1000 counts 
Allowed ion species [H +], [Na +] and [NH4 
+] [H +], [Na +] and [NH4 
+] 
 
This example illustrates how the number of molecular features is highly dependent on the 
MFE parameters. The parameters used in this study, setting A, are set according to the noise 
ration from one injection. Further evaluation of these setting could be performed. 
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Matrix effect is a well-known drawback in LC-MS that may lead to either ion suppression or 
ion enhancement of analytes, due to co-eluting residual matrix components. Artificial urine 
is a matrix of salts that is used for preparing calibration standards for methods used in 
diagnostics where ion suppression appears.  
 
In this study, the degree of matrix effects was evaluated for the developed method by 
comparing signals from compounds from the Magic mix standards spiked (1:1) in batch 
urine, artificial urine and H2O respectively, and peak area of selected compounds are 
compared in Figure 17.    
 
 
Figure 17: Evaluation of matrix effects by comparing the peak area of compounds in the Magic mix spiked in 
batch urine, artificial urine and H2O respectively.  
 
The endogenous compounds creatinine, deoxyadenosine and hippuric were found at highest 
levels in the batch urine as expected. Similar signals of deoxyadenosine, succinylacetone, 
hippuric acid and hexanoylglycine in the artificial urine and H2O, indicates a small degree of 
matrix effects. For creatinine, it was observed lower signals in artificial urine than in water. 
No obvious explanation for higher levels of alloisoleucine found in artificial urine rather than 
in H20 was found.      
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3.3.2 Sample stability 
 
In laboratory diagnostics it is well known that some compounds have limited stability. The 
preanalytical factors can be crucial to obtain reliable results. Secondly the stability will 
influence the allowable length of the analysis series, and thereby what time limit should be 
set between the start of the analysis until the last sample is injected. Stability of the batch 
urine was examined by analysing samples after 0-5 days of storage in room temperature. 
From the TICs (results are not shown), no significant changes between the chromatograms 
were found. The number of molecular features were detected with MFE is shown in Table 
18. 
 
Table 18: The number of molecular features detected in batch urine stored in room temperature for 0-
5 days. The samples were separated on ACE C18 PFP (250 x 2.1mm, 3 μm) column and detection was 
performed in positive mode. Injection volume was 5.0 μL and the used gradient is provided in Table 6. 
The data were collected in mass range m/z  100-1700.  
Days stored in room 
temperature 
# molecular features  
0 5527 
1 5227 
2 6331 
3 5941 
4 6601 
5 6631 
 
The results show that the number of molecular features increased with increased storage 
time at room temperature, which indicates compound degradation and eventually oxidation. 
The number of molecular features was fairly stable after one day at room temperature. 
Nevertheless, after 2 days in room temperature, the number of compounds increased 
significantly and will therefore be the limit of analysis series time.  
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3.4 Evaluation of developed method 
 
Repeatability of analytical methods is a measure of precision within a series. Normally, the 
expected coefficient of variance (CV) should not exceed 5-10 %. For global metabolomics in 
particular, both repeatability and reproducibility should be evaluated throughout the run. In 
this study repeatability of the developed LC Q-TOF MS method was evaluated with regard to 
tR and signal intensity precisions within one series. Batch urine was injected 10 times in one 
series according to developed method provided in the Experimental section. The results are 
shown as overlaying TICs in Figure 18.  
 
 
Figure 18: Chromatograms (TICs) shows 10 injections of batch urine injected in one series. The injection 
volume was 8.0 μL and separation was performed on an ACE C18 PFP (250 x 2.1 mm, 3 μm) column with the 
gradient described in Table 6. Detection was carried out in positive mode and data were collected in the 
mass range m/z 100-1700.  
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Five unidentified compounds were randomly selected throughout the gradient and the 
respective tR, peak area, height and CV % is provided in Table 19.  
 
 
Table 19: Mean value of tR, peak area and peak height, calculated for five randomly selected compounds in 
batch urine after 10 injections in series for evaluation of the repeatability of the method, see Figure 19.   
Compound tR mean (range)  
CV % 
Peak area mean (range) 
CV % 
Peak height mean (range) 
CV % 
I 5.1 (5.0 - 5.1)  
0.4 % 
3.5 (3.3 - 3.7) 108 
4.5 % 
1.8 (1.7 - 1.8) 107 
1.0 % 
2 10.4 (10.3 - 10.5) 
0.7 % 
6.2 (5.3 - 6.7) 106 
6.9 %  
6.0 (5.5 - 6.3)105 
4.2 % 
3 25.1 (25.0 - 25.2) 
0. 2 % 
3.5 (2.2 - 4.6) 107 
18.5 % 
3.1 (2.5-4.4) 106 
18.8 % 
4 33.1 (33.1 - 33.2) 
0.15 %  
31 (2.9 - 3.3)108 
4.6 % 
1.8 (1.7 - 1.8) 107 
2.4 %  
5 49.8 (4.8 - 4.9) 
0.1 % 
1.2 (1.2 - 1.4)107 
5.4 % 
1.6 (1.6 - 2.0) 106 
20.9 % 
 
The CV % for tR, peak area and peak height range was calculated to 0.4-0.7 %, 4.5-18.5 % and 
1.0- 20.9 % respectively. The peak area of compound 3 was significant higher mean value 
and the reason for this is not known. A slight trend was observed in which peak area for 
several of the selected compounds was either all low or all high in the same sample.  
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Reproducibility of analytical methods is a measure of precision between series, and is 
essential in diagnostic laboratories. In this study reproducibility of the developed LC Q-TOF 
MS method was evaluated by injecting batch urine aliquots from freezer, 10 times over a 
period of three weeks. The overlaying TICs are shown in Figure 19.  
 
 
 
 
 
Figure 19: Chromatograms (TICs) show 10 injections of batch urine between different series. Injection 
volume was 8.0 μL and separation was performed on an ACE C18 PFP (250 x 2.1 mm, 3 μm) column with the 
gradient described in Table 6. Detection was carried out in positive mode and data were collected in the 
mass range m/z 100-1700. 
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Five unidentified compounds were randomly selected throughout the gradient and the 
respective tR, peak area, height and CV % is provided in Table 20.  
 
Table 20: Mean value of tR, peak area and peak height, calculated for five selected compounds in batch 
urine after 10 injections in series for evaluation of the repeatability of the method, see Figure 20.   
Compound tR mean (range)  
CV % 
Peak area mean (range) 
CV % 
Peak height mean (range) 
CV % 
6 4.7 (4.4 - 4.7) 
4.6 % 
3.1 (2.7 - 3.5) x 108 
9.8 % 
1.8 (1.7 - 1.8) x 107 
1.9 % 
7 11.2 (10.9 - 11.6) 
1.9 % 
3.07 (2.7 - 3.5) x 108 
16.5 % 
8.4 (6.7 - 9.8) x 105 
14.1 % 
8 25.1 (24.9 - 25.4) 
0.7 % 
3.6 (2.8- 5.5) x 107 
25 % 
2.9 (2.2 – 4.0) x 106 
22.0 % 
9 35.4 (35.2-35.5) 
0.3 % 
2.7 (2.2 - 3.3) x 108 
14.9 % 
1.4 (1.4 - 1.7) x 107 
32.2 % 
10 39.8 (39.6-40.04) 
0.3 % 
3.6 (2.5 – 4.9) x 107 
28.8 % 
3.8 (2.6 - 5.1) 106 
21.8 % 
 
The CV % for tR, peak area and peak height range was calculated to 0.3-4.6 %, 9.8-28.8 % and 
1.9- 32.2 % respectively. A weak tendency of the peak area and peak height increasing 
throughout the run was observed for these particular compounds.     
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3.5 Intra- and inter- individual biological variation of the normal urinary metabolome 
 
The term “intra-individual biological variation” describes continual changes over a short or 
long period, within one individual as a result of diet, activity, hormones etc., while “inter-
individual biological variation” describes differences in the urinary metabolome due to 
diverse lifestyle, age and genetic differences. Both terms need to be considered in 
metabolomic studies. In this study, two different experiments were set up in order to obtain 
a better understanding about the inter- and intra- individual biologic variation of the normal 
urinary metabolome.   
 
3.5.1  Investigation of the intra- individual biologic variation  
 
The intra-individual biological variation was investigated by analyzing samples from healthy 
volunteers with individual diet of own choice. It was emphasized that the volunteers should 
eat normally. A group of 15 healthy volunteers (10 women and 5 men) participated. One 
urine sample was collected over a period of 10 work days, collecting a total of 10 urine 
samples per volunteer. Morning midstream urine was collected after 5:00 am in specific 
tubes and frozen at -20 ° C at home and at -70° C after arrival at the hospital and until 
analysis. Diet, including all food and drinks through the whole day prior to the day of urine 
collection in addition to eventual work out lessons was noted in a scheme delivered out prior 
to the experiment. Sex, age, weight, height, eventual nutrition subsidizations or medications 
and eventual vegetarian diet was also noted in the scheme. An example of scheme is 
provided in appendix (chapter 8.4). Due to lack of time, the samples were collected, but are 
not yet analyzed. Figure 20 shows a PCA-score constructed in MPP shows a urinary profile 
for 3 healthy volunteers with different diets over 10 days. 
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Figure 20: The PCA-score constructed is based on the molecular features shows a profile for 3 healthy 
volunteers with different diets over 10 days. 
 
The PCA-scores shows a clear tendency of clustering of each subjects’ metabolome over a 10 
days period. This could reflect limited variation in each person’s diet, or genetically driven 
differences between individuals in how the metabolism is regulated. From the information 
about the diet intake from each volunteer, no particular trend could be observed.  
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3.5.2 Investigation of the inter-individual biologic variation 
 
The inter-individual biological variation was investigated by analyzing urine samples from 
healthy volunteers with identical diet. A group of 14 healthy volunteers (10 women and 4 
men) participated over 3 days. On the first day the volunteers ate and drank according to 
own preferences and they were instructed to report every meal. Next day, a morning 
midstream urine sample was collected. During the second day, all volunteers were instructed 
to eat and drink identical food that was provided. The menu which included breakfast, lunch, 
dinner and supper was developed with emphasis on simple food and small degree of 
variation, with the aim of recruiting a sufficient number of participants for the trial. General 
information about the experiment, instructions for the procedure given to the participating 
volunteers is provided in appendix (chapter 8.5), in addition to the menu set for this day. On 
the third day, a second morning midstream urine sample was collected. All urine samples 
were frozen at -20 ° C at home and at -70° C after arrival at the hospital and until analysis. 
 
Principle component analysis (PCA) perfomed in MPP of urine samples from 15 healthy 
volunteers identified with a letter (A-O), from day 1 and 2 identified with shape (square and 
triangle) see Figure 21 was constructed. Day 1 represents different diet and day 2 
standardized diets. Square shape day 1 and triangle day 2.  
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Figure 21: The PCA-score constructed is based on the molecular features shows a profile for 15 healthy 
volunteers with identical diet for one day. 
 
The results indicate clustering of the points after standardized diet for 24 hours. The outliers 
on day one are united to a larger extent in day two, which indicates a rapid change in the 
metabolome as a result of diet.  
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The urine samples were also analyzed on 1H NMR by Daniel Sachse. Results are presented in 
Figure 22. Each volunteer is identified with a letter and attached number 1-2 indicates if the 
sample is collected after different diet (no 1) or identical diet (no 2). As expected the 
samples collected after day 1, is quite scattered while the samples collected after day 2 is 
more grouped together. The samples A2, K2 and J2 diverge from the rest of the samples 
from day 2. F1 is also close to this group. According to declared information from the 
volunteers A, K and J, there are no obvious reasons for the diverging points, and they are not 
the same sex or age. Since the volunteers I and J which are identical twins are not the closest 
points, which was rather unexpected since the genetics plays an important role when it 
comes to metabolism.    
 
Figure 22: 
1
H NMR PCA experiment healthy volunteers. Black dots represents the urinary metabolome from 
15 healthy volunteers having diets of own choice, while the red dots represent a standardized diet.  
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4 Future perspectives 
The developed LC Q-TOF MS method useful for both positive and negative ionisation, 
utilizing a global approach has shown ability to detect a large number of molecular features 
in urine. The samples that have already been collected during the diet experiments should 
be analysed and further investigation regarding biological variation should be performed. 
The outliers in the PCA-scores constructed should be investigated for correspondence to 
specific foods. Following that, the method should be used for establishing of the normal 
metabolome by collecting samples from a healthy population. Secondly, samples from 
patients suffering from a known IEM should be analysed and compared to the established 
normal profile to test the usefulness of the developed method. Finally, samples from the 
diagnostic biobank should be analysed in order to search for new diagnostic biomarkers and 
possibly describe new IEM. The method can also be used to investigate the biochemical 
consequences of, and by that identify more sensitive biomarkers for known IEM.  
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5 Spotlight project: Identification of unknown human urine 
metabolite UK460  
 
 Background – Identification of an unknown compound in a black urine sample. 
 
A urine sample from the patient was received at the Section of Inborn Errors of Metabolism 
for analysis of calculi. The sample did not contain a defined not contain a defined calculi, but 
rather precipitate of unknown origin. Normal components of calculi are calcium, phosphor, 
oxalic acid, uric acid etc. Calculus is a stone formed in the body that might cause medical 
conditions like kidney stone or bladder stone. In addition, drug-induced stones are known, 
and some rare kidney stones are seen in IEM; hypoxanthine stones, 2,8-dihydroxy adenine 
stones and cysteine stones. No common stone component was identified in routine analysis. 
However, it was observed that the urine sample turned from a regular yellow sample into a 
dark, black color by deferral on the bench. Most samples are thrown to waste after analysis, 
and so was this sample. Black urine is a common indicator of alcaptonuria (ACU) which is an 
IEM and a new sample was received for follow up analysis. ACU is known genetic disorder, 
where homogentisic acid oxidase is defect and homogentisic acid accumulates as a result. 
The clinical picture of ACU is dark pigment spots in the skin and yellow urine turning black 
when exposed to air and oxidation occurs, see Figure 23.  
       
 
Figure 23: Homogentisic acid is the patognomonic biomarker for diagnostics of the IEM alcaptonuria. The 
reduced form does not contribute to color in urine, while the oxidized form result in black urine by deferral 
on the bench or by adding NaOH. 
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While waiting for arrival of the new patient sample, the usefulness of the developed LC Q-
TOF MS method for identification of ACU was tested. A black urine sample from a patient 
already diagnosed with ACU was taken from the diagnostic biobank and analyzed. The 
diagnostic metabolite homogentisic acid [M+1]+ = m/z 169 with fragmentation pattern is 
shown in Figure 24. The spectrum was identical to the spectrum obtained by analysis of 
homogentisic acid dissolved in water (results not shown).  
 
Figure 24: Mass spectrum shows the fragmentation pattern of homogentisic acid m/z 169 analyzed by LC Q-
TOF MS in positive ionization.  
 
5.1.1 GC-MS analysis 
 
Sample preparation including methylation and GC-MS analysis of organic acids in urine were 
performed by the staff at Section for IEM according to standard operation procedure. 
 
The new urine sample from the same patient was yellow at arrival and was methylated 
according to standard procedures before analysis with GC-MS. Neither homogentisic acid 
nor any other known biomarker was could be detected and the patient was not diagnosed 
with ACU. In the following, the various approaches to reveal the cause of the black color of 
the urine are presented. Although homogentisic acid was not found in the patient urine, a 
signal with great intensity was measured, but the source or structure of the compound was 
not known. The compound had been detected once in the past, but it was not identified and 
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therefore given the identity name of “Unknown 460” (UK460). The mass spectrum in Figure 
25 shows the fragmentation of UK460 by GC-MS.  
 
Figure 25: GC-MS mass spectrum of methylated UK460 m/z 209    
What was particularly interesting was that two compounds with identical mass spectrum 
chromatographed both after 42 and 70 minutes, see Figure 26. The intensity of the latter 
peak was remarkably higher than the first. The questions arising were how UK460 
chromatographing after 42 and 70 minutes, respectively, could have different tR and if they 
had the same origin.   
 
Figure 26: The two GC chromatograms show UK460 eluting both after 42 and 70 minutes. 
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From the GC-MS spectrum the methylated molecular ion mass was determined to be M = 
209. A calculation of probable combination of the chemical elements in the structure was 
done under supervision by Per Ola Rønning, using Excel for low resolution GC-MS data, see 
appendix (chapter 8.6). The calculation was performed from the isotopic pattern and the 
abundance of the isotopes M+1, M+2 and M+3. The calculation was performed under the 
qualification of the compound having at least one nitrogen atom and two oxygen atoms 
since it was suspected to contain a carboxyl group. A Solver-procedure was performed (only 
for compound eluting at 70 min, due to highest intensity) to test different combination for 
the methylated molecular formula with best compatibility with the isotopic pattern. The 
number of C, H and O-atoms was calculated and the likely formula of C10H11NO4 was 
suggested. Subtracting a mass of 14 leaves a formula of C9H9NO4 with mass 195 which fits 
well with LC Q-TOF MS data. From the molecular formula the number of double bonds was 
calculated to be 6. In order to determine the structure, more information was required.  
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5.1.2 LC-MS/MS 
The black urine patient sample was analyzed by LC Q-TOF MS with ESI. The chromatographic 
most abundant peak eluted at 25 min, contained m/z 196 and m/z 391, respectively, see 
Figure 27. This compound appearing as the large peak was thought to be corresponding to 
the unknown compound UK460 detected by GC-MS at 42 and 70 min and not found in 
healthy batch urine which indicates an exogenous compound. The MS/MS spectrum from 
the two co-eluting compounds m/z 391 and m/z 196 are shown in Figure 28. The fragment 
patterns from m/z 391 shows that the most abundant daughter ion is m/z 196.This indicated 
the presence of a monomeric and dimeric form of the molecule.  
 
 
 
 
 
Figure 27:  TIC and EIC of m/z 196 and m/z 391 of black urine analyzed by LC Q-TOF MS ESI positive ionization 
mode. The large peak eluting at 25 min in the patient sample was not visible in the batch urine. Separation 
was carried out on a Kinetex C18 (100 x 2.1 mm, 2.6 μm) column, utilizing gradient elution in Table 8. 
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Figure 28. LC-MS/MS spectrum of black urine with identical fragmentation of the monomer ([M+H]
+ 
= m/z 
196) and dimer ([2M+H]
+
 = m/z  391)   
 
GC-MS cannot be performed on underivatized samples. Thus, in order to be able to compare 
Q-TOF data with GC-MS data, the methylated patient urine sample was also analyzed by Q-
TOF. By comparing the Q-TOF results obtained by analyzing the methylated and non-
methylated sample, structural information of the unknown compound can be obtained. The 
sample was analyzed before and after exposure to air, meaning both a yellow and black 
edition of the same sample. Even though the black urine sample is unusual and interesting in 
itself, it was not certain that the unknown compound had anything to do with the color.  
The chromatographic most abundant peak contained two different masses of m/z 210 and 
m/z 419 respectively, with identical eluting at 36 min, see Figure 29. The retention was 
stronger after methylation of the compound and the split top could possibly be due to the 
high concentration. 
 
 
 
Mass charge ratio (m/z)
In
te
n
si
ty
(c
o
u
n
ts
)
MS/MS m/z 196
MS/MS m/z 391
 70
 
Figure 29: TIC, EIC of m/z 210 and m/z 419 of methylated black urine analyzed by LC Q-TOF MS ESI positive 
ionization mode.  The large peak eluting at 35 min in the patient sample was not visible in the batch urine.  
 
The MS/MS spectrum from the two co-eluting m/z 210 and m/z 419 are shown in Figure 30. 
The fragment patterns from m/z 419 shows that the most abundant daughter ion is m/z 210 
and the further fragmentation patterns are identical.  
 
Figure 30: LC-MS/MS spectrum of methylated black urine shows identical fragmentation of the monomer 
([M+H]
+
 = m/z 210)  and dimer ([2M+H]
+
 = m/z 419)   
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It is interesting to note that in GC-MS, two peaks appear at different tR with the same 
spectrum, while in Q-TOF two different versions of a molecule (monomer and dimer) 
appears at the same tR, but with different MW for GC-MS. Perhaps the monomer and 
dimmer are stable during GC and thus are chromatographically separated, but when 
entering the EI source they are fragmented giving identical spectrum. In contrast in LC Q-
TOF, the monomer and dimer show the same chromatographic properties but are disclosed 
as two different molecules (monomer and dimer) in the softer ionization technique used for 
the Q-TOF, where the molecular ions can be detected. 
 
Although, UK460 at this point was regarded to be a compound able to form a dimer, there is 
still no certainty if there is a connection between the black color observed and UK460. To 
investigate the origin of the black color, the sample was centrifuged and black precipitate 
collected. After drying, the precipitate was dissolved in water and analyzed by LC Q-TOF MS.  
A distinct peak eluting at 2.2 minutes was observed, referred to as “compound X” in the 
following (see Figure 31). This points to UK460 being a compound that tends to dimerisate. 
Total ion chromatogram (TIC) and extracted ion chromatogram (EIC) of X m/z 154.08 eluting 
after 2.2 min is shown in Figure 31 and fragmentation pattern of UK460 m/z 196, eluting 
after 26.1 minutes is shown in Figure 28. While the monomer of UK460 was found, the dimer 
of UK460 m/z 391 could not be identified in dried precipitation.
 Figure 31. TIC of dried precipitation from black patient urine resolved in water and injected on LC-MS Q-TOF 
(black) , EIC 5-ASA [M+H]
+
  = m/z  154.08 eluting after 2.2 min and fragmentation pattern of N-Acetyl-5-ASA 
[M+H]
+  
= m/z 196 eluting after 26.1 min. The separation was performed on a Kinetex C18 (100 x 2.1, 2.6 μm) 
column, the injection volume was 5.0 μL and ESI positive ionization was utilized. Gradient used is shown in 
Table 8.  
 
The MS/MS product ion spectrum s of dried precipitate from black patient urine are shown in 
Figure 32. 
 
Figure 32: MS/MS product ion spectrum of dried precipitation from black patient urine, showing 
fragmentation pattern of component X with m/z  154 eluting after 2.2 min. 
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From a new patient a urine sample where UK460 had previously been detected by GC-MS, was 
analyzed by LC Q-TOF MS to compare mass spectrum to confirm that the same compound with 
mass of 390 was present. Chromatograms are shown Figure 33. (The mass spectrum are not 
shown) 
 
Figure 33: TIC and EIC of m/z 196 and m/z 391 of yellow patient urine sample analyzed by LC Q-TOF MS ESI 
positive ionization mode. The large peak eluting at 43 min in the patient sample was not visible in the batch 
urine. Separation was carried out on a C18 Diphenyl (250 x 2.0 mm, 3 μm) column, utilizing gradient elution in 
Table 8.  
 
The difference in retention time compared to UK460 in black urine (see Figure 27) can be 
explained by separation by a longer column. Once detection of UK460 in black urine, there were 
first made theories regarding the correlations between UK460 and the black color. However, 
after detection of UK460 in normal looking yellow urine it became quite uncertain about these 
correlations. However, the intensities of UK460 in black urine were significantly higher than in 
yellow urine. 
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5.1.3 NMR 
The unknown compound UK460 had been detected in black and yellow urine sample from two 
different patients. As MS was not alone able to identify the unknown compound, it was decided 
to analyze the samples with NMR to collect additional data for determining the structure. The 
sample preparation and 1H NMR 600 Hz analysis were performed by Daniel Sachse at Dept. of 
Chemistry (UiO). More details are provided in appendix (chapter 8.7).  
 
Three different samples were analyzed by 1H NMR: black urine with UK460, yellow urine with 
unknown compound UK460 and batch urine without UK460 as control. 1D-specra from analysis 
of black patient urine with, yellow urine and batch urine are shown in Figure 34, 35 and 36, 
respectively.  
 
 
Figure 34: 1D-spectrum of black urine analyzed by 
1
H NMR. 
 
 
 
SU
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Figure 35: 1D-spectum of yellow urine analyzed by 
1
H NMR.  
 
 
 
 Figure 36: 1D-spectum of batch urine analyzed by 1H NMR. 
 
In black urine peaks of high intensity in the aromatic area around 7 ppm was observed. These 
peaks also were detected in the yellow patient urine with UK460, however in lower 
concentration. The spectrum of the black urine is downscaled and thus cannot be compared to 
the yellow urine nor be used for quantitative measures.  
BaBatch urine
ppm
GuYellow urine
ppm
 76 
Based on these NMR results, it was demonstrated that UK460 was likely to contain of an 
aromatic structure. UK460 was not detected in batch urine which strengthens theory of this 
compound being exogenous. To sum up: NMR provided further information about the structure. 
However, UK460 was still not identified. 
 
5.1.4 FT-IR spectroscopy 
Analyses by LC, GC and NMR were not sufficient in order to determine the structure of UK460.  
Fourier transform infrared spectroscopy (FT-IR) of the precipitate from the black urine sample 
was performed on a Vertex 70 spectrometer (Bruker, Germany) under supervision by Sachin 
Chavan at the Dept. of Chemistry, (UiO) Catalysis group, for the purpose to identify functional 
chemical groups of UK460. The resulting Kubelka-Munk spectrum ranging from 4000 cm-1 to 360 
cm-1 is presented in Figure 37.  
 
 
 
Figure 37: FT-IR Kubelka-Munk spectrum of precipitate from black urine and possible functional groups present. 
 
An attempt to identify functional groups of the precipitate from the black urine was performed. 
However, identification of UK460 still appeared to be quite difficult.  
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5.1.5 X-ray diffraction  
X-ray diffraction (XRD) of the precipitate from the black urine sample was performed on a 
Discover D8 Diffractometer (Bruker, Karlsruhe, Germany) by researcher Sigurd Øien at Dept. of 
Chemistry (UiO), Catalysis group. The purpose was to investigate potential crystalline compounds 
in the sample, since precipitation in urine was observed. The resulting XRD diffractogram is 
shown in Figure 38. 
 
 
Figure 38: X-ray diffractogram of dried precipitation from the black urine sample. 
 
The large peak at 20° is considered as noise resulting from compounds in the plastic due to 
sample preparation. Sharp peaks in the diffractogram appearing between 8° and 30° indicates 
crystalline compound (s). The diffractogram was compared to a standard database and the 
compound 5-ASA was confirmed present in the precipitate from the black urine sample.  
 
Summary and concluding remarks on the compound X, main component in the precipitation, was 
identified as 5-ASA by XRD. Following this, the reference compound was bought and standard 
solution analyzed and compared to the results obtained when analyzing the patient sample. 
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5.1.6 Identification of black colour by LC-UV, spectroscopy and MS 
 
Black urine was analyzed by LC-UV to determine if the compound 5-ASA was causing the unusual 
black color, by collecting the peak manually. UV absorbance of the black urine shown in Figure 
39, strengthens the hypothesis that the compound in black urine eluting at 29 min does have 
something to do with the accumulated peak and potentially the black color.  
 
Figure 39: LC-UV chromatogram of black urine. 10 μl was injected onto aRP Eclipse XDB C18 prep 250 x 9.4 mm, 5 
μm column (Agilent, USA). Gradient elution was performed according to Table 8. A Perkin Elmer HPLC system 
with an Agilent autosampler and 200 series pump with a flow of 3.0 ml/min. UV absorbance of black urine was 
measured at 250 nm by a Waters tuneable detector 486, and chromatogram generated by the software 
TotalChrom Navigator. 
Batch urine was also analyzed using the same method as black urine, and a comparable peak 
could not be detected, see Figure 40. 
 
Figure 40: LC-UV chromatogram of batch urine, utilizing the identical conditions as provided in Figure 39.  
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The collected peak in black urine was injected directly into Esquire 3000 Plus MS ion trap (Bruker 
Daltonics) to identify the UV-absorbing compound present in black urine. The analysis was 
performed at Dept. of Chemistry (UiO) under supervision by associate professor Steven. R. 
Wilson. The MS spectrum in positive ionisation mode is presented in Figure 41. As can be seen, 
the spectrum contains the characteristic peak m/z 196. The highest peak m/z 214 could possibly 
be detection of N-Ac-5-ASA and H2O. 
 
 
Figure 41: MS spectrum of collected peak in black urine by LC-UV analyzed on ion trap shows peak 196.  
 
The MS/MS spectrum of this peak revealed the same fragmentation pattern (results not shown) 
as found for UK460, see Figure 28. 
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5.1.7 UV Spectroscopy 
The metabolite N-Ac-5-ASA was collected in fractions from LC-UV, but appeared to be 
transparent by eye. Due to the high dilution (1:300) of the collected fraction in LC-UV the sample 
was analysed by UV-Visible Spectrophotometer Cary Bio 100 (Varian) to determine if N-Ac-5-ASA 
absorbs UV and therefore might be causing the colour of the dark urine. The analysis was 
performed at Dept. of Chemistry (UiO) under supervision of Steven. R. Wilson. UV detection was 
performed in a range between 1000-200 nm and the resulting spectrum is presented in Figure 
42. 
 
 
Figure 42: UV-VIS spectroscopy measurement of manually collected peak in black urine by using LC-UV, see Figure 
39.  
 
From this UV-VIS spectrum shows that the compound is strongly UV absorbent. However, the 
result does not immediately explain how the black urine could be a result from N-Ac-5-ASA 
alone. However, this sample was quite eluted and could possibly obtain further result when 
having N-Ac-5-ASA if present in very high concentrations.  
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5.2 Confirmation and concluding remarks  
 
Compound X, the main constituent of the precipitate was identified as 5-ASA by XRD. Knowing 
the identity of this compound, the spectrum obtained from UK460 was investigated and it 
became clear that UK460 was a second metabolite with the same origin as 5-ASA. 
 
After the compound UK460 was identified as a metabolite from an anti-inflammatory drug, 
Salicylazosulfapyridine, which was also confirmed by the ordering physician. Further 
confirmation was obtained by analyzing a urine sample from another patient that was on the 
drug and analyzing on LC Q-TOF MS (results are not shown).    
 
5-ASA and N-Ac-5-ASA are known metabolites of Salicylazopyridine [41], see Figure 43. 
 
 
Figure 43: 5-ASA and N-Ac-5-ASA are known metabolites from the anti-inflammatoric drug 
Salicylazosulfapyridine. 
 
 
 
 
N
N
H
S
OO
N
N
OH
O
HO
H2N
OH
O
HO
N
OH
O
HO
H
O
Drug:
Salicylazosulfapyridine
Phase I metabolite:
5-ASA, MW 153
Phase II metabolite:
N-Ac-5-ASA, MW 195
 82 
Based on the fragmentation pattern resulted in LC-MS and GC-MS data, Per Ola Rønning has 
purposed a possible mechanism, shown in Figure 44. 
 
Figure 44: Purposed mechanism of fragmentation of N-Ac-5-ASA, both non-methylated (m/z 195) and methylated 
(m/z 209) respectively. 
 
 
The LC-MS analysis of the urine sample found the metabolite N-Ac-5-ASA both as a monomer 
[M+H = m/z 196] and dimer [2M+H = m/z 391]. However, the complex of the dimer or 
dimerization process is still not known. 
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6 Conclusion 
This master thesisdescribes the development of a robust method for global metabolomics in 
urine using LC ESI in positive ionization mode coupled to Q-TOF MS. An ACE C18 PFP (250 x 2.1 
mm, 3 um) column separated most compounds compared to 6 other RP columns. Furthermore, 
the method was improved by using an hour long gradient with the result that approximately 
6000 molecular features were detected in batch urine. Urine sample preparation was performed 
by using 0.22 μm cellulose acetate spin filters before injecting 8.0 μL onto the column. The 
method provided sufficiently promising characteristics to be a strong candidate method for 
future urinary metabolome analysis.   
 
In order to study of the whole urinary metabolome, the method was also used successfully in 
negative ionization mode, where approximately 7000 molecular features were detected. A 
significant overlap is expected in metabolites found in normal urine samples such as the batch 
urine between positive and negative ionization. Attempts to investigate the overlap between the 
ionization modes were made using a range of different approaches, but the complexity and size 
of the data set made this comparison difficult. However, in the search for new diagnostic 
metabolites it is uncertain which ionization mode will provide measurable signals; therefore both 
modes must be measured in order to detect a complete metabolome.  
 
The usefulness of this method was demonstrated by investigating intra- and inter- individual 
biological variation as a function of diet. The results in Figure 21 show a significant clustering of 
human urinary metabolites after eating a standardized diet for 24 hours, a novel finding 
indicating a surprisingly fast change in the metabolome.  
 
Using the method developed, in combination with a broad range of analytical techniques, an 
unknown compound in black urine from a patient was successfully identified as 5-ASA. Even 
though this compound turned out to originate from an anti-inflammatory drug, the workflow 
shows strong potential as a detection method for new diagnostic biomarkers in the future. 
 
The ability to measure the entire metabolome has enormous diagnostic potential and the 
method developed here have been shown to work exactly as required. This is an exciting step 
 84 
towards a diagnostic tool and the test results already provide new insights into the dynamics of 
the human metabolome. 
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8 Appendix 
8.1 Poster presented at the 20th Norwegian symposium on Chromatography in 
Sandefjord 2012 
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Anja Østeby 1,2, Siv Merete Løvoll1,2,Yngve Thomas Bliksrud1, Elsa Lundanes2 og Katja B. P. Elgstøen1
Innledning
Medfødte stoffskiftesykdommer (IEM – ”Inborn errors of metabolism”) utgjør en stor gruppe genetiske sykdommer som skyldes feil i metabolismen og  
medfører dermed en endring av metabolomet.1 Nye IEM oppdages og karakteriseres ved nye diagnostiske metabolitter blir funnet. For å få en større 
forståelse av de biokjemiske endringene ved IEM, må først normalmetabolomet beskrives. Uselektert metabolomikk i urin skal utføres ved hjelp av 
massespektrometri (MS) av typen quadrupol-time of fight (Q-TOF) i kombinasjon med væskekromatografi (LC). Elektronsprayionisasjon (ESI) med positiv 
ionisering vil generelt gi god følsomhet fordi en stor del av metabolomet vil la seg ionisere ved protonering. Det skal utvikles en LC Q-TOF metode som er 
både robust og reproduserbar, og ulike kolonner og mobilfaser skal testes og sammenliknes ved analyse av referansestoffer og batchurin. Metoden som 
skal utvikles, vil være et kompromiss som fungerer godt for både positiv og negativ ionisering, se poster ”Utvikling av LC QTOF metode med negativ 
ionisering for metabolomikkstudie av urin i forbindelse med medfødte stoffskiftesykdommer”. 
Metode
En standard blanding av 9 endogene stoffer (Figur 1) som 
skilles ut i urin ble laget for å undersøke hvordan kjente 
stoffer med ulike kjemiske egenskaper kromatograferer. 
Standard blanding ble laget i henholdsvis vandig prøve og i 
kunstig urin (salter) for å kunne avdekke eventuelle 
matrixeffekter. En reell batchurin ble samlet fra 2 friske 
personer. Standard blanding i vann, standard blanding i 
kunstig urin og batchurin ble filtrert gjennom 0,22 µm 
sprøytefilter før injeksjon på LC Q-TOF.
Omvendt fase kromatografi ble benyttet for 3 ulike 
analysekolonner (SP vist i i poster ”Utvikling av LC QTOF 
metode av LC QTOF metode med negativ ionisering for 
metabolomikkstudie av urin i forbindelse med medfødte 
stoffskiftesykdommer”) valgt ut fra rådføring med 
leverandører:
1. Atlantis T3 C18 3 µm 2,1*150 mm (Waters)
2. Kinetex C18 2,6 µm 2,1*100 mm (Phenomenex) 
3. ACE C18 PFP 3 µm 2,1*150 mm, med C18 PFP 
forkolonne (TeknoLab) 
Anvendt mobilfase: A (100 % H2O + 0,1 % FA) og B (100% 
MeOH). Gradienteluering ble benyttet for de 3 kolonnene i 
henhold til Tabell 1.
Funksjon ”Find by molecular feature” ble benyttet for å
undersøke hvor mange unike metabolitter som blir funnet 
ved analyse av batchurinen med de ulike kolonnene.
Diskusjon og konklusjon
Metabolitter med ulike kjemiske egenskaper er best egnet til å la seg ionisere positivt 
(eksempel kreatinin) eller negativt (eksempel sitronsyre) og begge metodene er derfor 
nødvending når urinmetabolomet skal kartlegges og nye diagnostiske metabolitter 
identifiseres. Det er små forskjeller i kromatografering av komponentene i std. blanding 
med de 3 kolonnene. For videre arbeid er det ønskelig å teste nye kolonner og ulike 
filtreringssteknikker før endelig metode bestemmes.
Kilder: 1. Janeckova H, Hron K, et al. Targeted metabolomic analysis of plasma samples for the diagnosis of inherited metabolic disorders. Journal of Chromatography A. In 
press 2010. 
LC/MS Q-TOF MED POSITIV IONISERING FOR METABOLOMIKKSTUDIE I URIN
1 Seksjon for biokjemisk genetikk 
ved Avd. for med. biokjemi, Oslo 
Universitetssykehus Rikshospitalet 
2 Kjemisk institutt, 
Universitetet i Oslo 
Figur 1: Komponenter i standard blanding i vann og 
standard blanding i kunstig urin
Tabell 1: Gradient eluering av batchurin, standard 
blanding i vann og standard blanding i urin
Foreløpige resultater
Ulike komponenter i std. blanding og batchurin ble separert med kolonnene Kinetex, 
Atlantis og ACE C18 PFP med LC/MS (Figur 2). Deoxyadenosin (A), Kreatinin (C), 
Parahydroxyfenyllaktat (D), Hippursyre (F), Hexanoylglycin (G) og Succinylaceton (H) ble 
separert og identifisert i std. blanding i vann og i kunstig urin (kromatogram 1-4). 
Sitronsyre (I) ble kun identifisert med Atlantis (kromatogram 3). Succionylaceton (H) 
kromatograferte dårlig på alle kolonnene. Kromatogram 1 og 2 av std. blanding i hhv. vann 
og kunstig urin tyder ikke på store matrixeffekter. Toppene som er merket * skyldes 
kontaminering i standarden av 3-hydroxybutyrat. Ukjente komponenter i batchurin ble 
separert med alle kolonnene (Figur 5-7), hvorav 2728 med Kinetex, 1936 med Atlantis og 
2914 med ACE C18 PFP. Batchurin med negativ ionisering er hentet fra ”Utvikling av LC 
QTOF metode med negativ ionisering for metabolomikkstudie av urin i forbindelse med 
medfødte stoffskiftesykdommer” har til sammenligning funnet 2863 ulike komponenter.      
Figur 2: Kromatogram  av hhv. batchurin, std. blanding i vann, std. blanding i kunstig urin, 
analysert på LC QTOF med ESI positiv ionisering, unntatt fig. 4 med negativ ionisering. 
Analysekolonnene Atlantis T3 C18, Kinetex C18 og ACE C18 PFP er testet med lik 
gradient, se tabell 1.        
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8.2 Example of class specific analysis  
Acylcarnitines will fragment in reproducible patterns and analysis by MS/MS is highly selective. A 
chemical modification involving butyl esterification of the aculcarnitines, fragments to produce a 
charged loss of 85 mass units, see Figure 44. The R-group is detected in a precursor ion scan. 
 
 
Figure 44: Butyl esterification of acylcarnitines produces a loss of 85 mass units and a neutral R-group, by 
collision induced ionization (CID). 
In the first mass separator (Q1) the intact molecular mass is measured. The molecules are then 
fragmented in a collision cell (Q2) before charged ions are measured in a second mass separator 
(Q3). Figure 45 illustrates the MS/MS set up for analysis of octanoylcarnitine (C8-carnitine). 
Intact butylated ion with mass of the specific acylcarnitine passes Q1. Q3 is set at m/z 85.  
 
Figure 45. Precursor ion scan of AC C8-carnitine analysis by MS/MS. Mass separator Q3 is set to scan m/z 85. 
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8.3 Artificial urine recipe obtained at OUS-RH 2012. 
 
 
 
 
 
Artificial urine. Chemical dissolved in 500mL water.  
 
 
Chemical (in Norwegian) Amount (g) 
 
Kaliumsulfat (K2SO4) 
 
 
0,85 
 
Urea (CH4N2O) 
 
 
10,0 
 
Dikaliumhydrogenfosfat K2HPO4 x 3H2O 
 
 
1,15 
 
Natriumklorid (NaCl) 
 
 
5,0 
 
Magnesiumsulfat (MgSO4 x 7H2O) 
 
 
0,6 
 
Kaliumdihydrogenfosfat  KH2PO4 
 
 
0,7 
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8.4 Out-handed protocols for the volunteers participating in the experiment for 
intra- individual biological variation  
(In norwegian) 
 
 
Innsamling av urinprøver for bestemmelse av intra- individuell biologisk variasjon 
 
 
 
Bakgrunn 
 
Medfødte stoffskiftesykdommer (IEM - Inborn Errors of Metabolism) utgjør et stort antall av 
genetiske sykdommer som involverer feil i metabolismen. ”Metabolom” er det totale settet av 
metabolitter i en biologisk prøve, for eksempel urin, og gir opphav til en såkalt metabolsk profil. 
For å få en større forståelse av de biokjemiske endringene ved IEM, må først 
”normalmetabolomet” beskrives. Utfordringen ved å undersøke normalmetabolomet er såkalt 
inter- og intra- individuell biologisk variasjon. Intraindividuell biologisk variasjon innebærer 
endringer av urinmetabolomet over korte eller lengre tidsrom hos ett enkelt individ. Endringene 
av metabolomet skjer kontinuerlig og kan gjenspeile ulikt kosthold, fysisk aktivitet og fysiologiske 
tilstander. Interindividuell biologisk variasjon innebærer forskjeller i urinmetabolomet mellom 
individer som kan skyldes ulik livsstil og genetiske forskjeller. I dette forsøket skal inter- og 
intraindividuell biologisk variasjon undersøkes ved analyse av urinprøver fra friske 
forsøkspersoner.  
 
 
Beskrivelse av prøvetakingen 
 
Prøvetakingen går over 10 testdager fra mandag til fredag i 2 uker, med vanlig kosthold og 
mosjon. Prosedyren for prøvetaking er illustrert i figur 1. På testdagene skal det samles inn 
midtstrømsmorgenurin (første urinering om morgenen, etter kl 05:00). Midtstrømsurin er den 
midterste porsjonen som kommer ut under urinering. Den første porsjonen av urinen skal rett i 
toalettet, deretter plasseres et prøverør under urinstrålen, og til slutt skal den siste porsjonen gå 
i toalettet. Urin skal samles direkte i utleverte prøvetakingsrør. Utleverte klistrelapper skal fylles 
ut og festes på prøverøret. Alle prøvene skal settes i fryseren umiddelbart etter prøvetaking. 
Inntak av mat og drikke, trening og eventuelle kommentarer skal fylles ut i innsamlingsskjema for 
hver prøve, som er gitt i tabell 3 og 4. Et eksempel på utfylt skjema er vist i tabell 2. Søndag før 
testukene er det ingen prøvetaking, men innsamlingsskjema skal fylles ut. Dersom det oppstår 
endringer ved prøveinnsamling som går utenom oppgitt prosedyre er det viktig at dette blir 
notert og at man fortsetter etter planen.  
 
Tips: Sett røret på toalettskålen på kvelden for ikke å glemme innsamling neste morgen! 
 
Kostholds- og treningsparametere vil IKKE bli linket sammen med personopplysninger i 
databasen.  
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LEV SOM NORMALT I FORHOLD TIL KOSTHOLD OG TRENING. 
Prosedyre for testdagene (man-fre) 
1. Prøvetaking i utlevert prøverør av midtstrømsmorgenurin etter kl. 06:00 
2. Notér forsøksperson, prøvenummer og tid på utlevert klistrelapp og fest på prøverør 
3. Sett prøverøret i fryser -70 ºC 
4. Fyll ut innsamlingsskjema i tabell 3 / 4 
5. Kommenter eventuelle avvik fra prosedyren 
 
 
 
 
 
 
 
 
 
 
Tabell 1. Generell informasjon om forsøkspers 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tabell 2. Eksempel på utfylling av innsamlingsskjema 
 
 
 
Eksempel 
Dag Prøvenr. Kosthold Trening (kl) Evt. kommentarer 
Mandag      
Dato:  01/01 1 
Kokt torsk, poteter, gulrøtter, 
smeltet smør, 2 kaffe, 1 glass 
rødvin. Grovbrød med gulost og  
paprika 
09:00 Klarte ikke å samle midtstrømsurin i prøverøret, bare siste porsjon av urineringen. 
Figur 4: Figuren illustrerer prøvetakingsmønster og prosedyre i løpet av prøveperioden over 2 uker. 
MandagSøndag OnsdagTirsdag FredagTorsdag
Innsamling av midtstrømsmorgenurin +utfylling av skjema.
Kun utfylling av skjema. 
INGEN prøvetaking
Testuke 1 og 2
Lørdag
God helg ☺
Forsøksperson:
Dato ved start (søn)
Fødselsdato:
Kjønn: Kvinne: Mann:
Vekt (kg):
Høyde (cm):
Kosttilskudd 
(medisiner) :
Vegeterianer: Ja : Nei: 
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Tabell 3. Innsamlingsskjema av urinprøver uke 1 
 
 
 
 
 
 
 
 
 
 
 
Prosedyre Dag Prøvenr. Kosthold Trening (kl) Evt. kommentarer 
Kun utfylling av 
skjema 
Søndag      
Dato:       
____/____ 
- 
Mandag           
Dato:       
____/____ 
1 
Tirsdag           
Dato:       
____/____ 
2 
Onsdag       
Dato:       
____/____ 
3 
Torsdag    
Dato:       
____/____ 
4 
Fredag      
Dato:       
____/____ 
5 
Testuke 1  
Prøvetaking av 
midtstrøms 
morgenurin og 
utfylling av skjema 
Ikke oppgi kosthold eller trening 
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Tabell 4. Innsamlingsskjema av urinprøver uke 2 
 
 
 
 
 
 
Kontakt Siv per tlf. 46935053 eller Anja per tlf. 98022811 ved endt prøvetaking eller evt. 
spørsmål. 
 
Takk for ditt bidrag til vårt masterprosjekt!! ☺ ☺ 
Prosedyre Dag Prøvenr. Kosthold Trening (kl) Evt. kommentarer 
Kun utfylling av 
skjema 
Søndag     
Dato:       
____/____ 
- 
Mandag     
Dato:       
____/____ 
6 
Tirsdag        
Dato:       
____/____ 
7 
Onsdag      
Dato:       
____/____ 
8 
Tor      
Dato:       
____/____ 
9 
Fredag      
Dato:       
____/____ 
10 
Testuke 2  
Prøvetaking av 
midtstrøms 
morgenurin og 
utfylling av skjema 
Ikke oppgi kosthold eller trening 
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8.5 Out-handed protocols for the volunteers participating in the experiment for 
inter- individual biological variation  
(In norwegian) 
 
 
 
Innsamling av urinprøver for bestemmelse av inter- individuell biologisk variasjon ved likt 
kosthold 
 
 
 
Bakgrunn 
Medfødte stoffskiftesykdommer (IEM - Inborn Errors of Metabolism) utgjør et stort antall av 
genetiske sykdommer som involverer feil i metabolismen. ”Metabolom” er det totale settet av 
metabolitter i en biologisk prøve, for eksempel urin, og gir opphav til en såkalt metabolsk profil. 
For å få en større forståelse av de biokjemiske endringene ved IEM, må først 
”normalmetabolomet” beskrives. Utfordringen ved å undersøke normalmetabolomet er såkalt 
inter- og intra- individuell biologisk variasjon. Intraindividuell biologisk variasjon innebærer 
endringer av urinmetabolomet over korte eller lengre tidsrom hos ett enkelt individ. Endringene 
av metabolomet skjer kontinuerlig og kan gjenspeile ulikt kosthold, fysisk aktivitet og fysiologiske 
tilstander. Interindividuell biologisk variasjon innebærer forskjeller i urinmetabolomet mellom 
individer som kan skyldes ulik livsstil og genetiske forskjeller. I dette forsøket skal interindividuell 
biologisk variasjon undersøkes ved analyse av urinprøver fra friske forsøkspersoner som har likt 
kosthold ut i fra en forhåndsbestemt meny.  
 
 
Beskrivelse av prøvetakingen 
Prøvetakingen går over 3 testdager, hvor prosedyren er illustrert i figur 1. På dag 1 skal kosthold 
og mosjon være som NORMALT og det skal ikke samles inn urin, se tabell 1. På dag 2 skal 
kosthold og mosjon bestemmes i henhold til en utarbeidet ”meny” hvor alle forsøkspersonene 
skal spise og drikke det samme, samt unngå trening, se tabell 2. På dag 3 er det ingen kostholds- 
eller mosjonsregulering, se tabell 3. På testdag 2 og 3 skal det samles inn midtstrømsmorgenurin 
(første urinering om morgenen) etter kl 05:00. Midtstrømsurin er den midterste porsjonen som 
kommer ut under urinering. Den første porsjonen av urinen skal rett i toalettet, deretter 
plasseres et prøverør under urinstrålen, og til slutt skal den siste porsjonen gå i toalettet. Urin 
skal samles direkte i utleverte prøvetakingsrør. Utleverte klistrelapper skal fylles ut og festes på 
prøverøret. Alle prøvene skal settes i fryseren umiddelbart etter prøvetaking. 
Tips: Sett røret på toalettskålen på kvelden for ikke å glemme innsamling neste morgen! 
 
Eventuelle kommentarer som avviker fra prosedyre skal fylles ut i innsamlingsskjema for alle 
dagene, som er gitt i tabell 5, 6 og 7. Et eksempel på utfylt skjema er vist i tabell 1, 2 og 3. 
Dersom det oppstår endringer ved prøveinnsamling som går utenom oppgitt prosedyre er det 
viktig at dette blir notert og at man videre fortsetter etter planen.  
 
 
OBS! Kostholdsparametere vil IKKE bli linket sammen med personopplysninger i databasen. 
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Prosedyre  
Dag 1:  
Lev normalt. Oppgi kosthold og eventuell trening i tabell 5.  
 
Dag 2: 
1. Prøvetaking i utlevert prøverør av midtstrømsmorgenurin etter kl. 05:00 
2. Notér forsøksperson, prøvenummer og tid på utlevert klistrelapp og fest på prøverør. Bruk 
vannfast markør!  
3. Sett prøverøret i fryser (-70 ºC hvis mulig) 
4. Fyll ut innsamlingsskjema i tabell 6. 
5. Følg forhåndsbestemt kostholdsmeny. Ikke tren.  
6. Kommenter eventuelle avvik fra prosedyren 
 
 
Dag 3: 
1. Prøvetaking i utlevert prøverør av midtstrømsmorgenurin etter kl. 05:00 
2. Notér forsøksperson, prøvenummer og tid på utlevert klistrelapp og fest på prøverør 
3. Sett prøverøret i fryser (-70 ºC hvis mulig) 
4. Fyll ut innsamlingsskjema i tabell 7.  
5. Kommenter eventuelle avvik fra prosedyren 
 
 
 
Figur 1: Illustrert prosedyre for utførelse for testdagene 1-3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dag 1 Dag 2
Innsamling av midtstrøms 
morgenurin
Bestemt kosthold
Ingen trening
Dag 3
Ingen prøveinnsamling
Notér i skjema: -Normalt kosthold
-Trening valgfritt
Innsamling av midtstrøms 
morgenurin
Kosthold og trening skal 
ikke oppgis
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Eksempel
Testdag 3 Prøvenr. Kosthold Trening (kl) Evt. kommentarer
    Dato:  
03/01/12 2 Ikke oppgi Ikke oppgi
Glemte å ta midtstrømsurin 
og samlet kun første "klunk"
Eksempler på utfylling av skjema for testdag 1-3 
 
Eksempel
Testdag 1 Prøvenr. Kosthold (i kronologisk rekkefølge) Trening (kl) Evt. kommentarer
    Dato:  
01/01/12
Ingen 
prøvetaking
                     Morgen                      
Frokost: Havrergyn med melk og       
sukker. Kaffe.                                        
Lunsj: Knekkebrød med gulost.          
Eplejucie. Banan.                                    
Middag: Spaghetti med kjøttdeigsaus     
og tomater. Kaffe. Eple                            
Kveld
Spinning (16.00) Begynner å bli forskjølet
 
 
 
 
 
 
 
Prøveinnsamling 
Tabell 4: Generell informasjon om forsøksperson 
 
 
Forsøksperson:
Kjønn: Kvinne: Mann:
Alder
Vekt (kg):
Høyde (cm):
Spesiell kost: 
(vegeterianer) Ja : Nei: 
Faste kosttilskudd / 
medisiner :
Allergier
Røyk / snus Ja : Nei:  
 
Eksempel
Testdag 2 Prøvenr. Kosthold Trening (kl) Evt. kommentarer
    Dato:  
02/01/12 1 Forhåndsbestemt meny Uteblir
Glemte meg og spiste Statros 
selv om den ikke var oppgitt i 
forhåndsbestemt meny
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Tabell 5. Innsamlingsskjema for testdag 1 
 
Testdag 1 Prøvenr. Kosthold Trening (kl) Evt. kommentarer
Dato:  Ingen prøvetaking
 
 
Tabell 6. Innsamlingsskjema for testdag 2 
 
Testdag 2 Prøvenr. Kosthold Trening (kl) Evt. kommentarer
Dato:  1 Forhåndsbestemt meny Uteblir
 
 
Tabell 7. Innsamlingsskjema for testdag 3 
 
 
Testdag 3 Prøvenr. Kosthold Trening (kl) Evt. kommentarer
Dato:  2 Ikke oppgi kosthold Ikke oppgi trening
 
 
Kontakt Siv per tlf. 46935053 eller Anja per tlf. 98022811 ved endt prøvetaking eller evt. 
spørsmål. 
Takk for ditt bidrag til vårt masterprosjekt!! ☺  
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Menu: 
 
Breakfast: Bread (medium dark), cheese (Norvegia), butter (Bremykt) and pepper (red) 
Lunch: Bread (medium dark), cheese (Norvegia), butter (Bremykt), pepper (red) and banana  
Dinner: Stew, pasta and salad 
Supper: Bread (medium dark), cheese (Norvegia), butter (Bremykt), pepper (red), banana 
(The participant were specifically asked to eat the banana after 21 pm) 
 
Only water was allowed to drink throughout the whole day. 
 
There was not put any restrictions about the size of portions. However, 2 slices of bread qualifies 
as 1 whole banana. If you only had one slice of bread for breakfast, you were only allowed to eat 
half a banana. 
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8.6  Isotope calculator constructed by Per Ola Rønning for identification of 
UK460 by GC-MS spectrum 
 
 
 
 
 
 
 
 
 
 
 
 
Analytt: UK460
Analyse-ID: C:\msdchem\1\DTA\FFAPrutine.D\20120123\1101001.D
Peak: 68,870 - 71,475 min (average)
Ion Abundance Norm Type
209,00 310220 100,00 M
210,00 36219 11,68 M+1
211,00 4498 1,45 M+2
212,00 362 0,12 M+3
Antall karbon fra binomialfomel
Antall, n 10,8
M+1 M+2
I-ratio 11,68 1,45 Avrund mass Molekylformel Umetylert
a C 10,2 10,0 120,0 C10H11NO4 C9H9NO4
b H 11,0 11,0 11,0 DBE = 6
c O 4,4 4,0 64,0
d N 1,0 1,0 14,0
e S 0,0 0,0 0,0
sum ratio 11,70 1,45 % 209,0
DBE 6,0 Forventet 209
Differanse 0,0
Intervall permited: 10 %
Low 10,51
High 12,84
Isotope abubdance
12C 98,93 % 13C 1,07
1H 99,988 % 2H 0,012
16O 99,757 % 17O 0,038 18O 0,205 %
14N 99,632 % 15N 0,368
32S 94,93 % 33S 0,76
34S 4,29 % 36S 0,02               
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8.7 NMR sample preparation and analysis for identification of UK460  
 
Three samples were analyzed: black patient urine sample with UK460, yellow patient urine 
sample with UK460 and a healthy batch urine control. 500 ul of each sample was mixed with 100 
μl distilled water and 50 ul buffer (KH2PO4/KOH, pH 7.4; D2O; TMSP-d4; NaN3) in an Eppendorf 
tube. The samples were centrifuged at 13400 g and 4 °C for 5 minutes, and 550 μl of each sample 
was transferred to 5 mm NMR tubes.  
The analyses were performed by a 1H NMR AV 600 Hz at temperature of 300.0 K.  
 
COSY spectrum, see Figure 46, of black urine shows that the six peaks are connected in two peak 
systems called A and B. (A: 7.7, 7.4 and 6.9 ppm; B: 7.3, 7.0 og 6.8 ppm; therefore: AABBAB). In 
yellow urine, most A was more abundant than B. 
 
 
 
Figure 46: COSY-spectrum from black urine analyzed by 1H NMR,  
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